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ABSTRACT 
 Synthesis and Evaluation of Biological Activity of a Potential 
Immunomodulatory Zwitterionic Polysaccharide 
Vikram Basava 
 
Doctor of Philosophy in Chemistry 
Seton Hall University 
Dr. Cecilia H. Marzabadi 
 
 
The gram-negative anaerobic bacterium Bacteroides fragilis is an integral component of 
the normal gastrointestinal flora. The bacterium colonizes the intestinal tract of human 
beings as it has no reservoir other than mammals. An unprecedented proportion of the 
genomic DNA of B. fragilus is involved in the production of capsular polysaccharides. 
These capsular polysaccharides are important virulence factors in most extracellular 
bacterial pathogens. Eight of these polysaccharides have been identified thus far, out of 
which two were found to be zwitterionic polymers, PSA1 and PSA2. PSA1 was found to 
stimulate T-cell lineage of the immune system because of the dual charge structural 
feature of the molecule. 
This dissertation discusses about the synthesis of a PSA1 analogue and evaluating its 
immunomodulatory activity. Also discussed are the synthesis and the chemical reactivity 
of 3,6-anhydro-D-glucal which was formed unexpectedly in the synthesis of L-rhamnal. 
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                                                            Chapter 1 
 
                                                 Introduction 
 
1.1 General Information 
 
The human immune system utilizes a variety of defense mechanisms to maintain the 
integrity of the human body. Recognizing, as well as differentiating between self and 
foreign antigens and defending the body from diverse infectious invaders are the major 
tasks of the immune system. The defense mechanisms consist of several protective 
measures such as natural barriers, non-specific (innate) as well as specific (adaptive) 
immune responses. Natural barriers are the first line of defense and are comprised of 
both physical, as well as, chemical barriers. Skin, being the toughest layer for a 
pathogen to overcome, is a physical barrier. Chemical barriers come into action when 
the integrity of the skin is compromised, often due to injury. Each region of the body has 
its own strategy and contributes to host defense against pathogens. Mucous 
membranes are protected by the secretion of anti-microbial immunoglobulins that can 
be found in saliva or tears. Mucous as well as cilia located in lower respiratory tract 
prevent colonization from pathogens. Similarly, the acidic pH in the gastrointestinal tract 
is an inhospitable environment for most microorganisms.1  
The second line of defense is the innate immune system, which acts on the antigens 
that penetrated the first line of defense, i.e., the skin and mucous membranes. Antigens 
are toxins or other foreign substances that induce an immune response in a body by 
producing antibodies. Innate immune responses which are found in all living organisms 
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are antigen independent and act immediately on the clearance of pathogens with a 
maximal response. The response is cell mediated and humoral, but, does not generate 
a lasting protective immunity because of the lack of immunologic memory. 
Microorganisms are detected and destroyed within minutes or hours by the various 
mechanisms of the innate immunity and occasionally causing perceptible disease in a 
normal, healthy individual.1  
The cells of the immune system originate from the stem cell. The stem cells produce 
myeloid progenitor cells as well as lymphoid progenitor cells. Myeloid progenitor cells in 
the bone marrow give rise to neutrophils, eosinophils, basophils, monocytes and 
dendritic cells. The lymphoid progenitor cells give rise to T-cells and B-cells. 
Macrophages and dendritic cells, which play a key role in innate and adaptive  
immunity, are derived from monocytes. Mast cells, which are fixed in tissues, develop 
from the same precursor cell as the circulating basophils. B-cells are produced in the 
bone marrow and are released into the blood the lymphatic systems. B-cells can further 
develop into plasma cells that secrete antibodies. Precursor T-cells undergo 
differentiation in the thymus into two distinct types of T-cells, the CD4+ T-helper cells 
and the CD8+ cytotoxic T-cells. Macrophages and dendritic cells function as bridges 
between innate immunity and adaptive immunity, since they present antigens to the 
immunocompetent T-cells which initiate an immunological response. Phagocytes 
involved in the innate immune system are macrophages, mast cells, dendritic cells and 
granulocytes. They act upon the antigens by breaking them down with the digestive 
enzymes in their lysosomes. Only when an infectious organism breaches these early 
lines of defense will an adaptive immune response ensue.1 
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The third line of defense is the adaptive immune system which comprises of the 
antigen-specific B-cell and T-cell lymphocytes. T-cells get involved with the B-cells, 
which have the ability to rearrange genes of the immunoglobulin family, as soon as the 
innate immune system signals the presence of a danger to the T-cells of the adaptive 
immune system. This results in the creation of diverse antigen-specific clones and 
immunological memory.2 The adaptive immune system then activates antigen-specific 
lymphocytes to proliferate and to differentiate into effector and memory cells that 
eliminate pathogens. Memory cells can prevent recurrence of disease caused by the 
same microbe. This highly sophisticated and potent adaptive immune system needs to 
be conducted, instructed and regulated by antigen presenting cells (APCs). 
1.2 Antigen Presenting Cells (APCs) 
Antigen Presenting Cells (APCs) include dendritic cells (DCs), macrophages as well as 
the B-cells. Bone-marrow derived APCs are present on peripheral blood and lymphatic 
tissues as well as in other organs to guard the host.1 DCs carry the antigens of the 
pathogen to the secondary lymphatic organs, the lymph nodes and the spleen. They 
also help in intracellular engulfing and degrading the antigens. 
The activity of the DCs depends upon the extent of their maturation. Immature DCs 
have a tremendous phagocytic activity to ingest antigens via pinocytosis or receptor-
mediated endocytosis. They have a number of receptors that enhance the uptake of 
antigens, and they are specialized to convert these antigens into Major 
Histocompatibility Complex (MHC)-peptide complexes that can be recognized by 
lymphocytes. Mature DCs lose their phagocytic activity and activate the adaptive 
immune system response by transforming into highly-effective APCs which have a very 
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short life span with no proliferation capacity.3 Upon antigen-mediated activation, DCs 
influence both the innate and the adaptive immune responses, thereby determining how 
the immune system responds to the presence of infectious agents.1  
1.3 Antigen processing and Major Histocompatibility Complex (MHC)-dependent 
antigen presentation in APCs 
Activation of the adaptive immune system by DCs is mediated by cytokine secretion and 
by direct presentation of antigens to T-cells. T-cells, which circulate between blood and 
peripheral lymphoid tissues, consist of T-helper, T-cytotoxic and T-regulatory cells. The 
CD4+ T-helper cells depend on the major histocompatibility complex (MHC) class II 
peptide-contact to initiate and modulate receptor- and cytokine-mediated functions of 
the immune system.4 CD8+ T-cytotoxic cells depend on the MHC class I by recognizing 
the endogenous antigens and mediating the cytotoxic immune system.5 MHC is a 
membrane glycoprotein encoded in a cluster of genes. It displays peptide antigen to T-
cells. T-regulatory cells suppress the immune response and protect the host from 
aggressive effector mechanisms of the immune system.  
Extracellular pathogens and proteins captured by APCs are either recycled to the 
plasma membrane or transported to the lysosome for degradation. They are then 
presented to the CD4+ T-cells through MHC class II proteins to induce an immune 
response.1, 6 Proteases, glycosidases and lipases present in endolysosomes are 
activated by low pH giving rise to protein degradation into smaller peptide fragments.  
The peptide needs to get loaded onto the MHCII molecule for it to present the antigen to 
a CD4+ T-cell.7 The MHCII molecules are present only on the professional APCs, unlike 
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the MHCI molecules. The MHCII molecule complex consists of two transmembrane 
glycoproteins, the α and the β, which form a non-covalently bound complex. The open 
ends on the peptide-binding groove of the MHCII molecules get filled and blocked when 
the invariant chain prevents uncontrolled early binding thereby targeting it to an acidic 
endosomal compartment. The activated proteases cleave the MHCII:invariant chain 
complex  when it enters the acidic endosomal pathway leaving a short fragment called 
class II-associated invariant-chain peptide (CLIP). Intracellular antigen loading of MHCII 
is dependent on HLA-DM, a MHCII-like molecule in humans (H-2M in mice) which is 
found predominantly in the MHCII compartment.8 The antigen first binds to the MHCII 
molecule, catalyzes the release of the CLIP fragment from the MHCII binding groove, 
stabilizes the MHCII molecule to prevent aggregation and aids in rapid and tight binding 
of peptides to the empty MHCII molecule. The MHCII:peptide complex is then 
transported from the lysosome to the cell surface and the peptide presented to CD4+ T-
cells.9 Once recognized, the CD4+ T- cells activate other effector cells of the immune 
system, like macrophages, which kill the intravesicular pathogens they harbor, or B-cells 
to secrete immunoglobulins against the foreign bodies.  
The B-cell antigen receptors are a membrane-bound form of antibodies which will be 
released upon activation, plasma cell differentiation and proliferation of the B-cell with a 
specific antigen. The MHCII:peptide complex must be stable at the cell surface. If it isn’t 
stable, the pathogen in the infected cell could escape detection or be picked by MHC 
molecules of an infected cell and be wrongfully destructed by cytotoxic T-cells.1 
There are about 30,000 antigen-receptor molecules, called T-cell receptors (TCRs) on 
the T-cells which consist of TCRα and TCRβ polypeptide chains linked by a disulfide 
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bond. The TCR on the cell surface recognizes processed and presented peptide 
antigens. The α:β heterodimers have a similar structure to the Fab fragment of an 
immunoglobulin molecule which account for antigen recognition by most T-cells.1 
1.4 Stimulation of T-cell activation by Dendritic cells (DCs) 
An immunological synapse made up of MHCII:peptide complexes on the DC and the 
TCR on the T-cells is formed when the mature DCs interact with the T-cells. This 
interaction leads to the activation of the T-cells by an intracellular signaling pathway 
which leads to the induction of differentiation and proliferation. The naïve T-cells 
proliferate and their progeny adhering to the APCs develop into armed effector T-cells.1 
The secretion of cytokines leads to the DCs further directing T-cell development 
towards Th1 and Th2 phenotypes via cytokine production.10 Interaction of immature or 
tolerogenic DCs with T-cells can result in T-cell deletion, anergy, or the generation of 
Treg cells.11 
1.5  Zwitterionic polysaccharides as T-cell-dependent antigens 
MHCII proteins were previously only known to present proteins, peptides or 
superantigens. Most of the known bacterial polysaccharides do not get processed or 
presented on the APC surface to T-cells, as they fall apart in the lysosomes of the 
APCs.6 But, recent in vivo and in vitro studies showed that some polysaccharides of 
certain symbiotic bacteria get transported from lysosomes to the cell surface to get 
presented by MHCII protein. This results in the activation of CD4+ T-cells in vitro and the 
induction of CD4+ T-cell-dependent abscesses in vivo.12,13,14,15,16 Hence, this discovery 
of the MHCII pathway being responsible for carbohydrate antigen presentation and 
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eventual T-cell recognition alters the previous fundamental model of MHCII-antigen 
binding.  
The CD4+ T-cell activation by bacterial polysaccharides is dependent on the transport of 
bacterial polysaccharides via MHCII. The functional role of HLA-DM is to help the 
bacterial polysaccharide to compete with peptides for MHCII binding.13,14  
The few polysaccharides which induce the CD4+ T-cell-dependent formation of 
abscesses in vivo are characterized by the presence of opposite charged motifs on 
each repeating unit. They are therefore termed as zwitterionic polysaccharides (ZPS). 
They include polysaccharides like PS A1 and PS A2, Sp1, and CP5 from the 
commensal bacteria Bacteroides fragilis, Streptococcus pneumonia and 
Staphylococcus aureus, respectively (Fig. 1.1).17 The presence of zwitterionic charges 
is critical for the antigenic function of the ZPSs. Removal of either of the charges on the 
ZPS resulted in compounds that failed to stimulate CD4+ T-cells.18  
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Fig. 1.1: Subunits of PSA1, PSA2, Sp1 and CP5 
1.6 T-cell-dependent immune responses: Peritonitis and abscess formation 
Secondary peritonitis, the most common one, is observed because of the loss of 
integrity in the gastrointestinal tract. This is due to the contamination of the peritoneal 
space by symbiotic intestinal bacteria.19 Development of intraperitoneal abscesses, a 
bacterial infection, is followed by colonic leakage of commensal intestinal bacteria. It is 
seen in patients with inflammatory bowel diseases (IBD) like Crohn’s disease or 
ulcerative colitis. Almost a third of patients infected with general peritonitis die in spite of 
improved diagnostic modalities, potent antibiotics, modern intensive care and 
aggressive surgical treatment.20 The surgical treatment for generalized peritonitis is 
through peritoneal lavage, drainage of localized abscesses, removal of the 
contaminating source by repairing, and drainage of the peritoneal cavity. However, even 
in the presence of improvised therapy, residual abscesses form in patients resulting in 
substantial morbidity and mortality.21 
Abscess formation is known to be a CD4+ T-cell-dependent immune response induced 
by ZPS.18 The zwitterionic charge promotes CD4+ T-cell-dependent abscess induction 
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in experimental murine and rat models.22 Chemical abrogation of the zwitterionic charge 
demonstrated that the charged nature of ZPS is critical for its ability to induce abscess 
formation. No CD4+ T-cell-dependent immune responses are observed for ZPS 
derivatives that have been made neutral or only possess a single charge (cation or 
anion).18 In contrast, uncharged polysaccharides induce T-cell-dependent immune 
responses after they are modified to possess a zwitterionic charge.18,23,24  
1.7 Bacteroides fragilis 
Bacteroides fragilis is a Gram-negative, anaerobic, bile-resistant, non-spore forming, 
rod-shaped bacterium whose primary known environmental reservoir is the human 
lower gastrointestinal tract where it lives as a commensal organism. They are significant 
clinical pathogens and are found in most anaerobic infections, with an associated 
mortality of more than 19%. The bacteria maintain a complex and generally beneficial 
relationship with the host when retained in the gut. They fermentation of carbohydrates 
in the human intestine results in the formation of a pool of volatile fatty acids which are 
reabsorbed through the intestine and utilized by the host as an energy source.25 But, 
when they escape from the gut, they can cause significant pathology including 
bacteremia and abscess formation in multiple body sites. Though B. fragilis accounts for 
only 0.5% of the human colonic flora, it is the most commonly isolated anaerobic 
pathogen because of its potent virulence factors. They have the most antibiotic 
resistance mechanisms and the highest resistance rates of all anaerobic pathogens. 
Clinically, Bacteroides sp. have exhibited increasing resistance to many antibiotics 
including cefoxitin, clindamycin, metronidazole, carbapenems and fluoroquinolines (e.g.,  
gatifloxacin, levofloxacin and moxifloxacin). 
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A distinctive feature of B. fragilis is the large proportion of the genome devoted to 
carbohydrate metabolism, including the degradation of dietary polysaccharides and the 
production of surface polysaccharides.26,27,28 The ability to express multiple capsular 
polysaccharides has been shown to enhance intestinal colonization by B. fragilis.29 Thus 
far, eight different capsular polysaccharides, each synthesized from different genomic 
loci, have been identified. Two of the capsular polysaccharides of B-fragilis, 
polysaccharide A (PSA) and polysaccharide B (PSB) belong to a class of carbohydrates 
known as zwitterionic polysaccharides (ZPSs). Previously, carbohydrates had been 
characterized as classic T-cell-independent antigens that induce a specific IgM 
response but fail to evoke an IgG or memory response.30,31 However, it is now known 
that ZPSs are capable of inducing CD4+ T-cell-dependent immune responses. All of the 
known ZPSs have immunomodulatory properties that depend on the presence of both 
positively and negatively charged groups within the repeating units.18,22,32 Of all the 
known ZPSs, PSA is the best characterized. 
PSA is a unique and potent antigen. Among carbohydrates, this polysaccharide stands 
out as a T-cell dependent rather than a T-cell-independent antigen. Although it is 
processed and presented along the same pathways as conventional peptide antigens, 
PSA modulates the host immune system more extensively than many other known T-
cell-dependent antigens. 
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1.8  PSA Structure 
 
 
                                                                                        
     
 
 
                                         Fig 1.2: Structure of Polysaccharide A (PSA) 
PSA is a zwitterionic polysaccharide, with an average molecular mass of 100 kDa, 
comprising of repeating tetrasaccharide units. The positive charge is situated at the free 
amino group of the rare 2-acetamido-4-aminofucose moiety and the negative charge 
resides on the carboxylate of the pyruvate ketal spanning C4 and C6 in the 
galactopyranosyl residue.  
1.9  ZPS-mediated CD4+ T-cell activation 
Activation of CD4+ T-cells requires the specific interaction of the α-β T-cell receptor 
(TCR) on the T-cell with the antigen presented in the context of MHCII on a professional 
APC.33 To induce an immune response, PSA must be processed in an endocytic 
pathway and presented on an MHCII molecule in a manner analogous to that by which 
peptide antigens are presented. The notable difference is that, in the endosome, the 
degradation of PSA to a molecule size small enough for presentation by the MHCII 
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molecule is a non-enzymatic chemical process. Whereas, protein degradation occurs 
enzymatically.33,34 Once taken up into an APC, PSA follows the same processing 
pathway as peptide antigens. Upon entry into the endosome of an APC, PSA is directed 
to a MHCII compartment. The up-regulation of inducible nitric oxide synthetase, which is 
associated with the oxidative burst, results in increased nitric oxide (NO) production. NO 
breaks down PSA through deamination, a chemical reaction in which PSA is oxidized 
and then depolymerized to a much smaller molecular size while retaining the 
zwitterionic motif and the overall structure of the repeating unit. Finally, co-localization of 
PSA, MHCII, and α-β TCRs can be detected on the cell surface of murine splenocytes 
by confocal microscopy. However, no PSA is found on the cells lacking MHCII.34 In the 
absence of direct contact between APCs and T-cells, ZPSs cannot stimulate T-cell 
proliferation or induce cytokine production in vitro.16  
1.10 Cytokines involved in T-cell-dependent immune responses 
Cytokines are of great importance in CD4+ T-cell-induced abscess formation. It has 
been suggested that cytokines may be responsible for triggering the migration of 
immune cells into the peritoneal cavity following contamination with B. fragilis.35 
Cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), IL-6, IL-12, IL-
15 and IL-18 are involved in T-cell activation as well as proliferation.36 It was 
demonstrated that ZPS PSA induces the production of TNF-α and IL-1α on peritoneal 
cells which act as significant immune mediators for abscess formation.37 When TNF-α is 
blocked, expression of the ICAM-1 (intercellular adhesion molecule-1) is significantly 
reduced leading to the accumulation of polymorphonuclear leukocytes (PMNLs) within 
the abdominal cavity. This then inhibits the formation of a peritoneal sepsis. 
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Furthermore, PSA stimulates the secretion of chemokines such as IL-8 which stimulate 
T-cells. 
IL-10, one of the most potent anti-inflammatory cytokines in the immune system, is 
required for PSA suppression of the inflammatory immune response. It plays a critical 
role in protection against inflammation in several animal models.  
During sepsis and peritonitis, IL-6 is considered as an import mediator of immunologic 
alterations in the host, along with TNF-α and IL-1.38 From the results observed, IL-6 is 
the most potent proinflammatory cytokines because it stimulates the expression of the 
broadest spectrum of acute phase proteins in inflammation and infection.39 
IL-6 is a pleiotropic inflammatory cytokine which is produced by a variety of cells. It acts 
on a wide range of tissues by stimulating the activation, survival and proliferation of 
CD4+ T-cells and acts on T-cells as an anti-apoptotic factor.40 IL-6 prevents apoptosis of 
normal and resting T-cells in the absence of additional cytokines. It has also been 
identified as a migration factor for human primary T-cells.41 In vitro experiments showed 
chemotactic activity of IL-6 on peripheral blood lymphocytes, lymphokine-activated killer 
cells, and CD4+ and CD8+ T-lymphocytes.42 IL-6 was also found to be linked to T-cell-
dependent immune diseases and autoimmune diseases such as the inflammatory 
bowel diseases, ulcerative colitis and Crohn’s disease.43  
1.11 Toll-like receptor (TLR) signaling 
Toll-like receptors (TLRs) are a class of proteins that play a key role in the innate 
immune system. They are single, membrane spanning, non-catalytic receptors usually 
expressed in cells such as macrophages and dendritic cells. TLRs play a critical role in 
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host defense by sensing the presence of microbes. They mediate inflammatory 
responses, coordinate innate and adaptive immunity, prime naïve T-cells, and induce 
memory to facilitate the elimination of pathogens, upon activation.44,45 The TLRs include 
TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, TLR11, TLR12, 
and TLR13. TLR12 and TLR13 are not found in humans. TLRs recognize certain highly 
conserved microbial components known as pathogen-associated molecular patterns 
(PAMPs). They even recognize other molecules like bacterial lipopolysaccharides, 
flagellin, bacterial DNA, and viral double-stranded RNA.46 Nevertheless, both 
pathogenic and commensal microbes produce the microbial ligands which are 
recognized by TLRs. Although TLR signaling was traditionally associated with the 
sensing of the pathogens, it is now appreciated that commensal bacteria are also 
recognized by TLRs, and that this interaction is critical for protection against epithelial 
injury and intestinal homeostasis.47  
The triggering of TLRs on DCs leads to the induction of co-stimulatory signals (e.g. 
MHCII) and to the production of cytokines that orchestrate T-cell recruitment, activation, 
differentiation and survival and are essential for the induction of adaptive immune 
responses.48 Likewise, the decrease in processing and presentation of PSA combined 
with the decreased production of IL-12 by dendritic cells activated by PSA in the 
absence of TLR2 signaling demonstrates that in addition to the stimulation of a specific 
CD4+ T-cell immune response, innate immune pathways are required for PSA to 
establish a Th1/Th2 balance.  
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1.12 Aim of the present study 
From what was discussed above, it is quite evident that ZPSs like PSA have the 
potential to induce CD4+ T-cell-dependent immune responses in vitro and are also 
capable of inducing abscess formation in vivo in a CD4+ T-cell-dependent manner. But, 
not much work has been done to date to study the potential to induce CD4+ T-cell-
dependent immune responses of simplified, zwitterionic polysaccharides which are 
analogous to PSA. 
We propose to study the synthesis of an immunomodulatory zwitterionic polysaccharide 
as well as its interactions with APCs and T-cells. The molecule synthesized will be 
evaluated for its ability to produce IL-6 and TNF-α in APCs. IFN-γ (T-cell response) and 
IgM (B-cell response) production will be studied using mouse spleen cells in co-culture 
with APCs. Finally, a cell proliferation assay will be done on the spleen cells of mouse.  
The initiation of both innate and adaptive responses by the ligands could prove to be a 
major step forward in the development of a carbohydrate-based vaccine.49 
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                                                        Chapter 2 
Synthesis and Biological Evaluation of a Potential Immunomodulatory 
Zwitterionic Polysaccharide 
2.1 General Information 
A considerable amount of work has been done for the synthesis of various zwitterionic 
molecules. The compounds synthesized were found to be of incredible importance in 
the field of science. Kowalczky50 reported the synthesis of alkylammonium zwitterionic 
amino acid derivatives (Fig 2.1). The molecules synthesized were characterized by 
FTIR, NMR spectroscopy and DFT calculations. The pharmacotherapeutic potential of 
the molecules synthesized was estimated by Prediction of Activity Spectra for 
Substances (PASS) which showed that the compounds could be used for as creatinase 
inhibitors, polyamine-transporting ATPase inhibitors, hydrogen dehydrogenase 
inhibitors and alkylacetylglycero-phosphatase inhibitors. They were even predicted to be 
useful as antiviral, antitoxic and antimutagenic agents. 
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Fig. 2.1 Synthesis of 3-(3-dimethylamonio)propylammonio propanoate bromide (a), 4-
(3-dimethylamonio)propylammonio butanoate bromide (b), 5-(3-
dimethylamonio)propylammonio pentanoate bromide (c)  
 
Similarly, Szoka, et al.,51 reported and synthesized a novel class of zwitterionic lipids 
with head groups containing a 3o or 4o amine and a carboxylate group. These lipids 
were found to form stable liposomes that exhibit head group dependent, pH-responsive 
biophysical characteristics which could make them suitable for drug delivery 
applications. 
Zwitterionic structure monomers such as phoshorylcholine52, sulfobetaine53 and 
carboxybetaine54 have been found to reduce protein absorption and platelet adhesion. 
Xu, et al.,55  incorporated these charged groups into polyurethanes (Fig 2.2) by 
synthesizing them from a polycarbonatediol with alkyne groups and 3-((azidoethyl) 
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dimethylammonio)propane-1-sulfonate using the copper catalyzed 1,3-dipolar 
cycloaddition (click) reaction.   
                                                 
 
                                                                  Fig. 2.2 Polyurethane 
 
Likewise, Bergstrom56 and others described the synthesis and the structure–activity 
relationships of zwitterionic spirocyclic compounds which are used as potent cysteine-
cysteine chemokine receptor-1 (CCR1) antagonists (Fig 2.3). A spirocyclic amine was 
treated with 3-bromo-2,2-dimethyl-propan-1-ol in the presence of NaI and Et3N in DMF 
to give the desired adduct which upon coupling with 4-fluoro-2-hydroxybenzoate in a 
Mitsunobu type reaction gave the ester adduct. The ester adduct was then treated with 
the racemate of methyl pyrollidine-3-carboxylate in the presence of carbonyl di-
imidazole (CDI) in N, N-dimethylformamide (DMF) to give a mixture of the 
diastereomers.  
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Fig. 2.3 (a) NaI, Et3N, DMF, 78 oC 60 h; (b) methyl 4-fluoro-2-hydroxybenzoate, Ph3P, DEAD, THF, rt 
20 h; (c) (R)-methyl pyrrolidine-3-carboxylate/(S)-methyl pyrrolidine-3-carboxylate, CDI, DMF, rt, 20 h  
Of the few known zwitterionic capsular polysaccharides, the structures of only a handful 
of them (PS A1 and PS A2, Sp1, and CP5 from the commensal bacteria Bacteroides 
fragilis, Streptococcus pneumonia and Staphylococcus aureus, respectively) have been 
characterized thus far (Fig 2.4).  
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                                                 Fig. 2.4 Zwitterionic polysaccharides (Subunits) 
 
Bundle, et al.,57 first synthesized the hexasaccharide representing two repeating units of 
the zwitterionic capsular polysaccharide from Streptococcus pneumoniae type 1 (Sp1). 
The synthesis involved the stereoselective construction of 1,4-cis-α-galactose linkages 
based on a reactive trichloroacetimidate donor that incorporates a 6-O-acetyl group 
which has been proposed to account for the α-selectivity in glycosylation.  
Later, Codee, et al.,58 came up with a modular approach towards the synthesis of all 
possible trimer repeating units of the Sp1 polysaccharide. For efficiently introducing α-
galacturonic acid bonds stereoselectively, galacturonic-[3,6]-lactone building blocks 
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were used. The building blocks not only acted as donor galactosides, but they were also 
functional as reactive acceptor glycosides when equipped with a free hydroxyl group 
(Fig 2.5).  
 
                               Fig. 2.5 Three frame-shifted trimer repeats of Sp1 polysaccharide 
 
Similarly, Bundle, et al., were successful in synthesizing a trisaccharide repeat of the 
zwitterionic Sp1 polysaccharide. 2-Azido-4-benzylamino-4N,3-O-carbonyl-2,4,6-
trideoxy-D-galactopyranosyl trichloroacetimidate (B), was synthesized in six steps from 
6-deoxy-D-glucal. The glucal was glycosylated with selectively protected α-1,3-linked 
methyl galabioside (C, D) to produce the trisaccharide skeleton of Sp1 (Fig 2.6).  
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Fig. 2.6 Trisaccharide repeat of zwitterionic Sp1 (A) and the monosaccharide synthons (B, C, D) 
 
PS A1, one of the zwitterionic capsular polysaccharides of Bacteroides fragilis, was first 
synthesized successfully by van der Marel, et al.,59 in its fully protected form (Path I, Fig 
2.7). One of the drawbacks of this synthesis is that the overall yield was low because of 
very low nucleophilicity of molecule B.  
Seeberger, et al.,60 later synthesized the same molecule by the [3+1] glycosylation 
technique, in its unprotected form (Path II, Fig 2.7). Glycosylation in this process took 
place between the highly electro deficient trisaccharide glycosylating agent C, and the 
pyruvated galactose nucleophile D. The –OH group on C3 of the galactose residue 
acted as a very good nucleophile. 
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Fig. 2.7 Retrosynthesis of PS A1 
 
For the de novo synthesis of the 2-acetamido-2-amino-2,4,6-trideoxy-D-galactose 
(AAT), N-Cbz-L-threonine (i) was used as the starting material (Fig 2.8). It was first 
converted to a methyl ester followed by acetylation to give (ii). Treatment of (ii) with 
lithium bis(trimethylsilylamide) (LHMDS) resulted in a Dieckmann cyclization61, 62 to give 
enoate (iii). The treatment of (iii) with 1,2-diisobutylaluminium hydride (DIBAL)63 gave 
(iv) which upon reduction under Luche64 conditions gave allylic alcohol (v). Acetylation of 
(v) followed by azidonitration65 gave (vii). Cleavage of the anomeric nitrate in (v) with p-
TolSH/DIPEA66 followed by reaction with 2,2,2-triflouroacetamidoyl chloride resulted in 
the formation of the N-phenyl trifluoroacetimidate sugar (A).  
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                                    Fig. 2.8 Synthesis of the AAT building block (A) 
Reagents and conditions (a) i., FmocCl, py., 0 °C, 79%; ii., BzCl, py., 0 °C, 82%; iii., TsOH, MeOH, 40 
°C; iv., CH3C(O)CO2Me, BF3·OEt2, CH3CN, 23 °C, 39%, two steps; (b) i., i-PrOH, NIS, AgOTf, CH2Cl2, 0 
°C; ii., NEt3, CH2Cl2, 23 °C, 49%, two steps; (c) LevOH, DIPC, DMAP, CH2Cl2, 0 to 23 °C, 90%; (d) i., 
NIS, THF, H2O, 23 °C; ii., F3CC(NPh)Cl, Cs2CO3, CH2Cl2, 0 °C, 83%, two steps; (e) i., NBS, EtOAc, H2O, 
23 °C, 91%; ii., F3CC(NPh)Cl, Cs2CO3, CH2Cl2, 23 °C, 87% 
The galactosamine derivative was earlier synthesized (Fig 2.9) by the initial treatment of 
(viii) with naphthyl bromide and NaH followed by cleavage of the benzylidene ring with 
TES and TFA in CH2Cl2 to give the 6-O-benzylated galactosamine derivative, (ix).67 
                               
                                     Fig. 2.9 Synthesis of the galactosamine derivative (ix) 
Reagents and conditions (a) NapBr, NaH, THF, 0 oC to 23 oC, 84%; (b) TES, TFA, CH2Cl2, 0 oC to 23 
oC, 81% 
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The galactosamine derivative obtained, (ix), was then glycosylated (Fig 2.10) with the 
AAT, (A), in the presence of TMSOTf in CH2Cl2 at 0 oC to give the disaccharide (x). 
                               
                                          Fig. 2.10 Glycosylation of the AAT building block (x) 
                                     Reagents and conditions (a) TMSOTf, CH2Cl2, 0 °C, 74% 
 
Similarly, the galactofuranose building block (xii), was synthesized (Fig 2.11) by 
reacting the known thiol68 (xi) with N-bromosuccinimide (NBS) to form the lactol, 
followed by the formation of the N-phenyl trifluoroacetimidate derivative (xii). 
                               
                                   Fig. 2.11 Synthesis of the galactofuranose building block (xii) 
Reagents and conditions (a) i., NBS, EtOAc, H2O, 23 °C, 91%; ii., F3CC(NPh)Cl, Cs2CO3, CH2Cl2, 23 
°C, 87% 
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The last building block, the pyruvated galactose sugar (D), was synthesized from the 
benzylidene galactoside (xiii).69 The C3 and C2 hydroxyl groups were initially protected 
with Fmoc70 and Bz groups respectively (Fig 2.12). Cleavage of the benzylidene acetal 
was followed by the formation of the pyruvate ketal71 (xiv) using BF3. OEt2. Finally, 
glycosylation of (xiv) with isopropanol in the presence of NIS/AgOTf followed by removal 
of the Fmoc protecting group gave the pyruvated galactose nucleophile (D). 
 
                  
 
                               Fig. 2.12 Synthesis of the pyruvated galactose nucleophile (D) 
Reagents and conditions (a) i., FmocCl, py., 0 °C, 79%; ii., BzCl, py., 0 °C, 82%; iii., TsOH, MeOH, 40 
°C; iv., CH3C(O)CO2Me, BF3·OEt2, CH3CN, 23 °C, 39%, two steps; (b) i., i-PrOH, NIS, AgOTf, CH2Cl2, 0 
°C; ii., NEt3, CH2Cl2, 23 °C, 49%, two steps 
 
In the synthesis of the trisaccharide (C), the first step involved the removal of the 
naphthyl ether group using 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) (Fig 
2.13). The resulting alcohol (xvi) was glycosylated with galactofuranose N-phenyl 
trifluoroacetimidate (xii) to give the trisaccharide adduct (xvii) as the β-anomer. The 
anomeric tert-butyl-dimethylsilyl (TBDMS) group was removed in the presence of 
tetrabutylammonium fluoride (TBAF) to give a lactol that upon treatment with 2,2,2-
triflouroacetamidoyl chloride in the presence of Cs2CO3 resulted in the formation of the 
N-phenyl trifluoroacetimidate adduct (xviii). Thioethyl glycoside (C) was later synthesized 
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from glycosyl imidate (xviii) by the reaction of the latter with ethanethiol (EtSH) in the 
presence of TMSOTf at 0 oC in the presence of 4 Ao molecular sieves. 
 
 
    
                                            Fig. 2.13 Synthesis of the trisaccharide, C 
Reagents and conditions (a) DDQ, MeOH, CH2Cl2, 23 °C, 86%; (b) TMSOTf, CH2Cl2, −30 °C, 90%; (c) 
i., TBAF, AcOH, THF, 0 °C; ii., F3CC(NPh)Cl, Cs2CO3, CH2Cl2, 23 °C, 82%, two steps; (d) EtSH, TMSOTf, 
4 Ao MS, CH2Cl2, 0 °C, 96% 
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The resulting trisaccharide (C) formed was made to react with pyruvated galactose 
moiety (D) in the presence of dimethyl (methylthio) sulfonium triflate (DMTST)72 and 
2,4,6-tri-tert-butylpyrimidine (TTBP) at 0 oC to give the totally protected PS A1 adduct 
(xix) in 58% yield (Fig 2.14). 
                    
                                         Fig. 2.14 Formation of the tetrasaccharide, (xix) 
Reagents and conditions (a) dimethyl (methylthio) sulfonium triflate (DMTST), 2,4,6-tri-tert-
butylpyrimidine (TTBP), 4 Ao MS, 0 oC, CH2Cl2 
 
Finally, the azide groups of fully-protected PS A1 (xix) were converted to acetamides 
using ethanethioic acid (AcSH) and pyridine (Fig 2.15). Global deprotection of the 
acetamide adduct of PS A1 was performed in two different steps. Initially, the compound 
was hydrogenated in the presence of Pearlman’s catalyst73 which removed the benzyl 
as well as the CBz groups. Next, NaOMe in MeOH/H2O was added dropwise to form the 
final PS A1 tetrasaccharide repeating unit in 46% yield.  
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                 Fig. 2.15 Deprotection and formation of PS A1 tetrasaccharide repeating unit 
Reagents and conditions (a) AcSH, py., 23 °C, 67%; (d) i., H2, Pd(OH)2/C, MeOH, 23 °C; ii., THF, then 
0.5 M NaOMe in 1:1 MeOH/H2O, 23 °C, 46%, two steps 
 
Earlier studies revealed that peptides synthesized to mimic the zwitterionic charge motif 
associated with zwitterionic polysaccharides exhibited biologic properties. Lysine-
aspartic acid (KD) peptides with more than 15 repeating units stimulated CD4+ T-cells 
in vitro and gave protection against abscesses induced by bacteria such as Bacteroides 
fragilis and Staphylococcus aureus.74  
Alterations made in the charge motifs of the zwitterionic polysaccharides were shown to 
have either partially or totally removed the stimulatory properties of the sugars.75 It was 
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also proved that the non-charged portions of the saccharide chain are not essential for 
the stimulation by PS A1. Modifications made to the non-charged sugars failed to 
diminish the production of cytokines.  
Discussed hereafter is the synthesis of an analogue of the PS A1 zwitterionic 
polysaccharide that could be of utmost importance in investigating its biological activity. 
Since only the charged sugar residues have been implicated in binding and processing 
of PS A1, the synthesis has been carried out using a commercially-available 
cycloalkane diol as the bridging moiety. As the galactofuranose moiety has zero charge 
on it, and as it doesn’t contribute to the size of the PS A1 moiety in increasing the 
distance between the charges (Calculated: 13 Ao; Observed: 15 Ao), we decided to not 
include it in the synthesis of the analogue. 
2.2 Results and Discussions 
2.2.1 Synthesis of the pyruvate-containing galactose moiety 
The synthesis of the pyruvated sugar moiety started with the commercially available β-
D-galactose pentaacetate (1). It was first made to react with 1.2 equivalents of 
thiophenol (PhSH) in the presence of BF3.OEt2 to give predominantly the anomeric β-
substituted thiophenol adduct (2) in 97% yield (Scheme 2.1).76  
                           
                   Scheme 2.1 Synthesis of β-thiophenyl-2,3,4,6-tetra-O-acetyl-D-galactopyranose 
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The thiophenyl adduct obtained was then de-acetylated using Zemplen’s conditions to 
yield 98% of the galactopyranose sugar (3) in 98% yield (Scheme 2.2).77 
                   
                                    Scheme 2.2 De-acetylation using Zemplen’s conditions 
 
A series of reactions were then set up to selectively protect the C4 and C6 hydroxyl 
functional groups. The best possible route chosen involved first forming of the 4, 6-O-
benzylidene protecting group. As the benzylidene ring is preferentially six membered, 
there is a greater chance of ring formation between the C4 and the C6 hydroxyl groups.  
The de-acetylated thiophenyl adduct (3) was treated with benzaldehyde dimethylacetal 
in the presence of camphor sulfonic acid in DMF at 65 oC (Scheme 2.3).78 However, 
TLC analysis of the reaction mixture showed that under these conditions esentially no 
reaction took place. A similar reaction was also carried out using the dimethyl acetal in 
the presence of p-toluenesulfonic acid. But, again there was no reactivity observed 
when monitoring by TLC.79 Reactions were set up separately with (3) using 
benzaldehyde and benzaldehyde dimethyacetal in the presence of pyridinium p-
toluenesulfonic acid. These reactions also did not show the formation of product. 
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                        Scheme 2.3 Various attempts in synthesizing the benzylidene sugar moiety 
 
When the reaction when set up in the presence of ZnI2 and benzaldehyde, none of the 
desired product was obtained (Scheme 2.3). But, the same reaction (Scheme 2.4)   
when repeated in the presence of ZnCl2 did give the desired benzylidene sugar (4) in 
65% yield.80 The formation of product was supported by the 1H NMR spectrum that 
showed a singlet at 5.53 ppm which represents the axial hydrogen on the 
benzylidene ring. 
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                                     Scheme 2.4 Synthesis of the benzylidene sugar moiety 
 
Compound (4) was subsequently reacted with dibutyltin oxide and benzoyl chloride in 
the presence of 4 Ao molecular sieves in toluene to give a mixture of 2-O-benzoyl and 3-
O-benzoyl sugar derivatives (Scheme 2.5). The latter, being the major product, was 
easily separated by flash column chromatography yielding 50% of the 3-O-benzoyl 
adduct (5a).81 
                                      Scheme 2.5 Selective benzoylation using organo tin chemistry 
 
Various attempts were made to protect the hydroxyl group at the C-2 position. A 
benzylation reaction was initially carried out by reacting compound (5a) with benzyl 
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chloride in the presence of NaH and 15-crown-5 in DMF (Scheme 2.6).82 As the 
reaction failed to occur, the benzylation reaction was attempted by using 
benzyltrichloroacetimidate and trifluoromethane sulfonic acid.83  But, again there was no 
product formation. Reaction of (5a) with p-nitro-benzyl bromide in the presence of NaH 
and DMF did not show the addition of the benzyl group at the C-2 position. Reaction of 
p-methoxylbenzyl chloride with (5a) in the presence of NaH and 15-crown-5-ether did 
not show the benzylation reaction happening, but instead resulted in debenzoylation 
giving (4) as the final product.84 This offside reaction could have occurred because of 
the formation of NaOH when NaH reacted with trace amounts of water in the solution.  
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                         Scheme 2.6 Attempted benzylation reactions at the C-2 hydroxyl group 
 
The reason for the lack of reactivity of the C-2 was likely due to the bulky nature of the 
protecting group used and the sterically crowded environment at that position. Hence, a 
smaller protecting group was used. A reaction was carried out between (5a) and acetyl 
chloride in the presence of triethylamine and N, N-dimethylaminopyridine which resulted 
in the formation of the 2-O-acetyl adduct (6) in 69% yield (Scheme 2.7).  
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                                        Scheme 2.7 Successful acetylation at the C-2 position 
 
The next step was to introduce a pyruvate moiety into the sugar. This could be done by 
cleaving the benzylidene ring and subsequently introducing the pyruvate functional 
group into the sugar. The benzylidene ring can be cleaved in different ways. Depending 
on the reagents used, there may form a 4-O-benzyl-6-hydroxy sugar or a 4-hydroxy-6-
O-benzyl sugar. But, for introduction of the pyruvate ring into the sugar, formation of the 
4,6-diol is imperative. Therefore, compound (6) was treated with 20% trifluoroacetic acid 
in CH2Cl2 to give a 4,6-diol sugar (7a, 45% yield).85 The diol sugar upon treatment with 
methyl pyruvate in the presence of BF3-Et2O gave the desired pyruvate sugar (7) in 
80% yield (Scheme 2.8).86 
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                                 Scheme 2.8 Addition of the pyruvate group to the sugar moiety 
 
2.2.2 Synthesis of the phthalimido adduct 
Various attempts were made in synthesizing the positive charged moiety having the 
amino group on it. First, glucosamine was made to react with acetyl chloride which gave 
the per-acetylated-2-acetamido α-glucopyranosyl chloride with a very good yield.87 The 
product was then reacted with thiophenol in the presence of Et3N in acetonitrile which 
gave the desired β-thiophenyl adduct.88 The obtained product showed no reactivity any 
further probably because of the formation of the stable oxazoline ring with the 
acetamido group at the C-2 position. Attempts in reacting the glucopyranosyl chloride 
with 1, 4-cyclohexanediol in the presence of N-iodosuccinimide and Yb(Otf)3 to yield the 
desired O-glycoside were not fruitful (Scheme 2.9).89  
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Scheme 2.9 Earlier attempts in synthesizing the thioglycoside 
Subsequently, glucosamine first was per-acetylated, and the product was treated with 
BF3. Et2O to give the oxazoline derivative. The oxazoline derivative when treated with 
thiophenol and camphor sulfonic acid (CSA) showed no reactivity.90 This can be 
attributed to the stability of the oxazoline ring. One-pot reaction for the addition of the 
thiophenyl moiety to the per-acetylated glucosamine in the presence of BF3. Et2O upon 
sonication did give the desired thiophenyl adduct.91 The reaction was found to have not 
reached completion (Scheme 2.9). 
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Having observed problems with the 2-acetamido group because of its formation of a 
stable oxazoline ring, plans were made to incorporate a phthalimido group as it doesn’t 
take part in the neighbouring group participation. Glucosamine HCl was first reacted 
with NaOMe in methanol to get glucosamine which was further reacted with phthalic 
anhydride in the presence of Et3N.92 The product (8) was then acetylated by reacting it 
with acetic anhydride and di-azo-bicyclooctane (DABCO) to give the desired per-
acetylated 2-phthalimido adduct (9) in 30% overall yield (Scheme 2.10).93  
 
Scheme 2.10 Synthesis of the 2-phthalimido adduct 
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The 2-phthalimido adduct (9) was then made to react with thiophenol in the presence of 
a mild base, Et3N. TLC of the reaction did not show the formation of the desired 
product. This was observed because of the bulkiness of the thiophenol group (Scheme 
2.11). 
               
Scheme 2.11 Substitution of thiophenol at the anomeric carbon atom 
Therefore, a smaller thiol, like ethanethiol, was chosen as the leaving group. Reaction 
of (9) with ethanethiol and BF3. Et2O in anh. CH2Cl2 gave the desired ethanethiol adduct 
(10) in 79% yield (Scheme 2.12).94 
 
                
Scheme 2.12 Substitution of ethanethiol at the anomeric carbon atom 
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2.2.3 Synthesis of the monosilylated 1, 4-cyclohexanediol 
Synthesis of the of one mono-protected hydroxyl group of 1, 4-cyclohexanediol 
selectively was not as challenging as the synthesis of the other subunits. First, the 
cis/trans mixture of 1, 4-cyclohexanediol was reacted with 1.2 equivalents of benzyl 
chloride and NaH in anh. DMF which gave a separable cis/trans mixture of mono-
benzylated product (11a, 11b) with an overall yield of 88% (Scheme 2.13).  
 
Scheme 2.13 Synthesis of the mono-benzylated adduct of 1, 4-cyclohexanediol 
 
But, from the earlier experiences, it was quite evident that debenzylation occurs when 
the reactions were carried out at elevated temperatures. Hence, attempts were made in 
substituting the benzyl group with a more robust silyl moiety. Reaction of 1, 4-
cyclohexanediol with 1.2 equivalents of tert-butyldimethylsilyl chloride and imidazole in 
anh. DMF gave the desired mono-silylated product (12a, 12b) in 50% yield as a white 
fluffy solid (Scheme 2.14).95 
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Scheme 2.14 Synthesis of the mono-silylated adduct of 1, 4-cyclohexanediol 
 
2.2.4 Synthesis of the final product 
Addition of thioethyl-2-phthalimido-3,4,6-tri-O-acetyl-β-D-glucopyranose (10) to the cis- 
mono-silylated adduct of 1,4-cyclohexanediol (12a) in the presence of trimethylsilyl 
trifluoromethanesulfonate (TMSOTf) and NIS in CH2Cl2 at -78 oC gave the desired 
product (13) in 1.5 h. The same reaction when allowed to warm up to room temperature 
gave the desilylated product (14) in 7 h (Scheme 2.15).96  
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Scheme 2.16 Reaction of compound (10) with (12) in the presence of TMSOTf and NIS 
 
Further reaction (Scheme 2.17) of the product (14) with the earlier obtained pyruvate 
adduct (7) in the presence of TMSOTf and NIS at -40 oC gave the final desired 
polysaccharide subunit (15). As the yields were incredibly low, no further steps were 
taken in deprotecting the final compound, and the obtained product was sent for 
biological evaluation. 
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Scheme 2.17 Synthesis of the PSA1 analogue 
2.3 Biological evaluation 
The protected PSA1 analogue (15) was evaluated using ELISA assays for the 
production of proinflammatory cytokines TNF-α and IL-6 (innate immunity). The cells 
used were the RAW 264.7 and the mouse peritoneal macrophages (C57, BL/6, Jackson 
Laboratories, Maine, US). Initial results showed (Fig. 16) that the cytokines produced by 
15 were negligible in comparison to those produced by the lipopolysaccharides, when 
analyzed on the RAW264.7 and the mouse peritoneal macrophages. 
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Fig. 16 Innate Immunity: Production of TNFα and IL-6 by RAW264.7 and the mouse peritoneal 
macrophages 
The compound (15) was further evaluated for adaptive immune responses on the 
spleen cells. The responses which were analyzed were for the T- and B-cell 
proliferation, levels of INF-γ in the supernatants which indicates a T-cell response, and 
polyclonal IgM and IgG levels in the supernatants which signifies a B-cell response. It 
was found that neither the T-cell nor the B-cell responses were observed with (15).  
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To elucidate the toll like receptor responsible for cytokine production, the peritoneal 
macrophages from TLR2 and TLR4 knockout mice (female, 4-6 weeks old, C57BL/6) 
were obtained. The cells were cultured with variable concentrations of the compound 
(15) and, the TNF-α and IL-6 levels in the supernatants were measured at different time 
points (Fig. 17).   
 
Fig. 17 Innate Immunity: Production of TNFα and IL-6 by the peritoneal macrophages from TLR2 and 
TLR4 knockout mice 
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It was observed that the production of both TNF-α and IL-6 was reduced in only the 
TLR4 knockout mice suggesting that signaling of (15) occurs only through TLR4. 
Furthermore, the graphical representation showed that the magnitude of TLR4 signaling 
with (15) was greater than the known TLR4 agonist, E. coli LPS (lipopolysaccharide). 
Similarly, the extent of binding of compound (15) to the TLR4 receptors was illustrated 
by treating the peritoneal exudate cells (PECs) with different concentrations of the 
compound. The cells were pre-incubated with the compound, after which they were 
washed. To the washed cells were then added the antibody followed by the 
phytoerythrin dye (PE) and, the number of the PE positive cells was observed by flow 
cytometry (Fig. 18). 
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Fig. 18 Results from flow cytometry 
 
The graphs in the figure above show that the increase in the concentration of the 
compound (15) results in an increased binding of the TLR-4 receptors to the compound. 
The graphs with TLR-2 show that the presence of the compound (15) doesn’t interfere 
with the cell count. This clearly depicts that the PSA1 analogue doesn’t bind to the TLR-
2 receptors. 
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                                                               Chapter 3 
         Synthesis and Chemical Reactivity of 3,6-Anhydro-D-glucal 
3.1 General Information 
Anhydrosugars (or intramolecular anhydrides) are the derivatives of monosaccharides 
obtained by the intramolecular elimination of a water molecule resulting in the formation 
of a new three-, four-, five-, six- or seven-membered heterocyclic rings. Their advantage 
of easy removal has led to the development of numerous derivatives, the synthesis and 
properties of which are described in the literature.97, 98, 99, 100, 101 These anhydrosugars 
are an important class of sugars which are used for the preparation of modified 
carbohydrates including the C-glycosides102, nucleosides103 and heterocyclic 
compounds104. They are also used in the synthesis of complex enantiomerically pure 
products where in the chirality of the parent sugar is transferred to the target via the 
chiron approach.105 They constitute very versatile starting materials not only in 
carbohydrate chemistry but also for the synthesis of non-carbohydrate and non-natural 
products. Anhydrosugars are the suitable monomers for preparing stereoregular 
polysaccharides and their specifically substituted derivatives.1 
For the synthesis of the anhydro skeleton in a normal sugar molecule, one of the 
hydroxyl groups of the diol which is taking part in the anhydro ring formation is 
converted into a leaving group such as a halogen, tosylate or triflate. The other hydroxyl 
group acts as a nucleophile resulting in the formation of the anhydro ring by an 
intramolecular SN2 approach (Fig. 3.1).  
 
57 
 
                                 
                            Formation of the anhydrosugar by elimination of the water molecule 
 
                                            Mechanism for the formation of the anhydrosugar 
                                                       Fig. 3.1 Synthesis of anhydrosugar 
The reaction protocols proposed by Mitsunobu106 and Castro107 for the synthesis of the 
anhydrosugars involve activation of the hydroxyl groups under milder conditions (Fig. 
3.2).  
     
                                   Fig. 3.2 Proposed protocols of Mitsunobu and Castro 
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The formation of anhydrosugars, may involve various carbon atoms of the sugar, thus 
leading to their categorization into different classes. They are divided into two main 
categories: 1. the anhydrosugars which involve the participation of the anomeric carbon 
atom, called glycosanes, which resemble the intramolecular glycosides; 2. the 
anhydrosugars which do not involve the anomeric carbon atom, called simply as 
anhydrosugars.1, 108, 109 The latter group comprises of purely synthetic materials which 
are exclusively used in synthetic carbohydrate chemistry. 
Classification of the anhydrosugars is also based on the heterocyclic ring formed upon 
dehydration. Oxirane (sugar epoxide), oxetane (oxacyclobutane), oxolane 
(tetrahydrofuran) and oxane (tetrahydropyran) are the various heterocyclic anhydrides 
known. Oxirane and oxetane rings show higher reactivity, whereas oxane and oxolane 
rings show comparatively low reactivity. The position of the anhydro ring, the steric 
arrangement as well as the conformation of the molecule also play a major role in 
determining the reactivity of the heterocyclic anhydrides.     
3.1.1 Glycosanes 
Compounds which are formed by the dehydration of the anomeric hydroxyl group and 
the terminal alcohol of a sugar molecule (1,6-anhydropyranoses, 1,6-anhydrofuranoses) 
or with any other alcohol on the sugar ring (1,2-, 1,3-, 1,4-anhydrosugars, etc) come 
under the class of anomeric anhydrosugars or glycosanes. The most common of these 
are the 1,6- and 1,2-anhydrosugars, while the others are less commonly seen in 
carbohydrate chemistry. They resemble conventional glycosides in their sensitivity to 
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acids by undergoing acid hydrolysis. But, highly strained anhydrosugars tend to 
undergo hydrolysis even in alkaline solutions.  
The formation of the carbocation at the anomeric carbon atom controls the 
regioselectivity of the opening of the ring.110 Nucleophilic attack occurs preferentially at 
the anomeric carbon atom resulting in the formation of various glycosyl derivatives or 
glycosides. The anhydrosugars act as monomers in polymerization reactions to form 
stereoregular polysaccharides, as the configuration of the corresponding anomeric, as 
well as the nonanomeric carbon atoms, remain the same. 
3.1.1.1 1,2-Anhydroaldoses 
1,2-Anhydroaldopyranoses have the 2,7-dioxabicyclo[4.1.0]heptanes skeleton which 
preferentially adopts 4H5 and 5H4 conformations.111,112 1,2-anhydrohexofuranoses have 
the more flexible 2,6-dioxabicyclo[3.1.0]hexane skeleton which adopts an E 
conformation. (Fig. 3.3).  
                   
                                                                Fig. 3.3 1,2-Anhydroaldoses 
Brigl was the first to synthesize the 1,2-anhydrosugar (Fig. 3.4).113 1,2-anhydro-3,4,6-tri-
O-acetyl-α-D-glucopyranose or ‘Brigl’s anhydride’ was prepared from β-D-glucopyranose  
pentaacetate by sequential treatment with PCl5 and NH3.114 The product was used in 
the synthesis of glycosides115 and α-D-linked disaccharides, like sucrose.116                                   
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                                                    Fig. 3.4 Synthesis of Brigl’s anhydride 
Subsequently, Danishefsky’s research group synthesized the 1,2-anhydrosugar by 
treating a glycal with dimethyldioxirane (Fig. 3.5).117 The product obtained upon 
treatment with a nucleophile gave the 2-hydroxy-β-D-glycoside.  
                             
                                        Fig. 3.5 Synthesis of 1,2-anhydride using dimethyldioxirane 
Similarly, Marzabadi, et al. synthesized the 1,2-anhydro glucal by making a halohydrin 
undergo a base induced cyclization (Fig. 3.6).118 Many other 1,2-anhydrides were 
synthesized later on. 
                                
                                          Fig. 3.6 Synthesis of 1,2-anhydride from a halohydrin 
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3.1.1.2 1,3-Anhydroaldoses 
1,3-Anhydrosugars have the 2,6-dioxabicyclo[3.1.1]heptane skeleton and may adopt the 
5C2, B2,5 or E2 conformation of the pyranose ring. The presence of axial substituents at 
C-2, C-4 and C-5 positions destabilize the 5C2 conformation (Fig. 3.7). The oxetane ring 
of 1,3-anhydrosugars is less reactive towards acids in comparison to the sensitivity of 
the oxirane ring in both acidic, as well as, in alkaline aqueous solutions.  
                              
                                                               Fig. 3.7 1,3-Anhydroaldoses 
Many of the 1,3-anhydrohexopyranoses of gluco-,119, 120 manno-,121, 122 galacto-,123 talo-
,124 and 6-deoxy derivatives125, 126, 127 were earlier synthesized via analogous 
procedures. They were obtained by reacting partially-protected glycosyl halides with 
strong bases like NaH and potassium tert-butoxide (Fig. 3.8). 
                         
                                          Fig. 3.8 Synthesis of a 1,3-anhydrohexose derivative 
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3.1.1.3 1,4-Anhydroaldoses 
The 1,4-anhydroaldoses have the 2,7-dioxabicyclo[2.2.1]heptane skeleton and adopt 
two non-interconvertible conformations, B1,4 and 1,4B (Fig. 3.9). They tend to be very 
stable in alkaline conditions, but get readily hydrolyzed in the presence of acids. The 
synthesis is similar to that of 1,3-anhydrosugars, and many compounds in the D-
gluco,128, 129, 130 D-galacto,131, 132 6-deoxy-L-manno, L-talo,133 L-arabino, D-ribo, D-xylo 
and D-lyxo configurations have been synthesized.134, 135, 136, 137, 138 
                                                   
                                                        Fig. 3.9 1,4-Anhydroaldoses 
3.1.1.4 1,6-Anhydroaldoses 
These compounds have the 6,8-dioxabicyclo[3.2.1]octane skeleton and have limited 
steric flexibility. Most of them adopt themselves to 1C4 conformation, while some of them 
are more flattened in B3,0 conformation. An inversion in the orientation at all the 
stereocenters is observed in comparison to the 4C1(D) and 1C4(L) conformations of the 
parent compounds. These anhydrosugars resemble methyl β-D-hexopyranosides in 
their chemical activity. They are very stable in alkaline conditions, but are very sensitive 
to acids (Fig. 3.10).  
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                                                                  Fig. 3.10 1,6-Anhydroaldoses 
Their synthesis includes cyclization of the hexopyranosyl derivatives having a good 
leaving group like halides, azides,139, 140, 141 tosylates142 or 2,4,6-trimethylbenzoates143 
at the C-1 position and alkali-sensitive glycosides, like phenyl glycosides,144, 145 by the 
action of strong bases. 
3.1.2 Anhydrosugars 
Compounds which are formed by the dehydration of any two hydroxyl groups on the 
sugar molecule, other than the hydroxyl group on the anomeric carbon atom, are the 
anhydrosugars. These heterocyclic anhydrides include the oxirane (sugar epoxides, 3-
membered), oxetane (oxacyclobutane, 4-membered), oxolane (tetrahydrofuran, 5-
membered) and oxane (tetrahydropyran, 6-membered) derivatives. 
3.1.2.1 Oxirane 
Oxiranes are the anhydro sugars having a fused oxirane ring to a pyranose or a 
furanose moiety. These have the 3,7-dioxabicyclo[4.1.0]heptane and 3,6-
dioxabicyclo[3.1.0]hexane basic skeletons that adopt either 5H0 or 1H0 conformations in 
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the ground state (Fig. 3.11). Generally the 2,3- and 3,4-anhydrohexopyranoses adopt 
the flexible half-chair conformation (H) depending on the presence or the absence of 
additional fused rings.  
                              
            
                                                                   Fig. 3.11 Oxiranes 
Though there exist many synthetic procedures for oxiranes, the most common 
procedure followed is the intramolecular SN2 nucleophilic displacement reaction. 
Usually, a tosyloxy or a mesyloxy group gets displaced by a vicinyl hydroxyl group that 
has been deprotonated by a base such as sodium methoxide.146, 147, 148 
These epoxy sugars are generally used in the synthesis of various derivatives of sugars 
like halo-, amino-, thio-, azido-, deoxy- and branched-chain derivatives. The oxirane 
ring, which is more reactive than oxetane and oxolane rings, opens in the presence of 
nucleophiles both in acidic and in basic conditions. But, it tends to be stable to catalytic 
debenzylation reactions (only palladium), in acylations and alkylations in basic media, 
and in detosylation reactions in the presence of nucleophiles. 
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3.1.2.2 Oxetane 
Anhydrosugars containing a fused oxetane ring in the 2,6-dioxabicyclo[3.2.0]heptane or 
the 2,7-dioxabicyclo[4.2.0]octane skeleton are called oxetanes (Fig. 3.12). 
                                    
                                                                   Fig. 3.12 Oxetanes 
 
3.1.2.3 Oxolane 
These include the bicyclic 2,5-anhydro- as well as the 3,6-anhydro-aldose derivatives. 
Their general skeleton is either 2,5-dioxabicyclo[2.2.1]heptane, 2,6-
dioxabicylco[3.2.1]octane or 2,6-dioxabicyclo[3.3.0]octane (Fig. 3.13). They exist even 
as monocyclic oxolane derivatives possessing a free aldehyde group. As they are quite 
stable in acidic and basic conditions, reactivity of these anhydrosugars is dependent on 
the presence or the absence of a free aldehyde group.                                          
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                                                                        Fig. 3.13 Oxolanes 
From the conformational analysis, it can be inferred that the relatively strained 2,6-
dioxabicylco[3.2.1]octane skeletons of 3,6-anhydro-D-gluco- and –D-manno-pyranose 
tend to rapidly recyclize into the less strained 2,6-dioxabicyclo[3.3.0]octane skeletons of 
the 3,6-anhydrohexofuranose in the presence of methanolic HCl. Such a rearrangement 
was not observed in the galacto- and talo- configurations.149, 150 
Many 2,5-anhydropentoses have been described so far, of L-arabino,151 D-lyxo, D-ribo 
and D-xylo sugars.152 Chitose or 2,5-anhydro-D-mannose is the most common 2,5-
anhydrohexose derivative.153, 154, 155 It can be prepared by the deamination of 2-amino-
2-deoxy-D-glucose. Other isomers include the derivatives of D-allose,156, 157 D-altrose, L-
idose,158, 159 D-glucose160, 161 and L-talose162. 
 Among oxolanes, 3,6-anhydroaldohexose derivatives form the major class. As per the 
configuration and conformation of all the eight possible 3,6-anhydroaldohexoses 
described, some of them exist as bicyclic pyranose, while others exist as bicyclic 
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furanose forms.163, 164 Hence, 3,6-anhydro derivatives of glucose and mannose adopt 
both the pyranose and the cis-fused forms, while those of galactose and talose adopt 
the pyranose form only. Gulose and idose can adopt only the cis-fused form. Likewise, 
free 3,6-anhydro-D-allose and –D-altrose can only exist in the acyclic form.165, 166 
3.1.2.4 Oxane 
Pyranose and furanose derivatives adopting either the rigid 2,5-
dioxabicyclo[2.2.2]octane skeleton with the pyranose ring in 2,5B or B2,5 conformation or 
the less flexible 2,6-dioxabicyclo[3.2.1]octane skeleton in 4C0 conformation are 
categorized as oxanes (Fig. 3.14). They comprise of 2,6-anhydrohexoses and 1,5-
anhydroketoses. Among the 2,6-anhydrohexoses, pyranoid derivatives in configurations 
of altro,167 ido,168 manno169 and talo170 configurations have been reported. Of the 
furanose derivatives, 2,6-anhydro-D-mannofuranose and its derivatives are known.171  
                                                           
                                                                          Fig. 3.14 Oxanes 
They can be synthesized by the reaction of sodium methoxide on the corresponding 6-
tosylate sugar (Fig. 3.15).172 1,5-anhydro-D-fructose is one of the 1,5-anhydroketose 
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sugars which is of particular interest.173 It is the central intermediate formed in the 
alternative glycogen catabolic pathway, also called as the Anhydrofructose (AF) 
pathway.174   
                  
                                      Fig. 3.15 Synthesis of a 2,6-anhydropyranose derivative 
 
3.2 Background 
The most widely known compounds from the tetrahedral class of anhydrosugars are 
3,6-anhydrofuranoses.175 Furanodictine A and B [Fig. 3.16] are good examples of this 
class that show neuronal differentiation activity.176 3,6-Anhydro-D- and L-galactoses and 
their partially methylated derivatives are typical constituents of polysaccharides of red 
algae.177 3,6-Anhydro sugars forming bicyclic nucleosides have shown antiviral 
activity.178 The puckering in the bicyclic carbohydrate moiety is believed to cause the 
molecule to be locked in the proper conformation for biological activity to be 
observed.179, 180 
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                                               Fig. 3.16 3,6-Anhydrofuranoses 
3,6-anhydrohexoses are considered to be of more importance as they are used to 
synthesize new nucleoside analogues.181 Reinhold et al. (1974) first synthesized 3,6-
anhydrohexose sugars by selective tosylation at the C-6 carbon atom followed by 
treatment of the intermediate tosylates with a strong base (sodium methoxide) (Fig. 
3.17). 182 Kreimeier et al. and Gross et al. substituted the hydroxyl group at C-6 by 
(Me2N)3P and halogens, upon which the tosylated sugars were treated with a strong 
base, as mentioned earlier.183, 184 Liptak et al. later confirmed that the presence of 
benzyloxy and methoxy groups at the C-3 position would help in the formation of the 
3,6-anhydride bond as they act as good internal nucleophiles. 185  
                         
                                              Fig. 3.17 Synthesis of 3,6-anhydropyranose 
Similarly, Shibayama, et al. and Santoyo-Gonzales et al. described the synthesis of 3,6-
anhydrohexofuranose derivatives by the basic solvolysis of 5,6-thionocarbonates, 
sulfates and sulfites.186, 187 A cyclic 3,5,6-orthoester was shown to have reacted likewise 
by basic solvolysis.188 Ishido et al. described the photochemical cyclization of a 
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substituted oxolane ring (Fig. 3.18).189 Yamaguchi et al. showed that the mercaptolysis 
of agar as a convenient method for the synthesis of 3,6-anhydro-L-galactose diethyl 
dithioacetal.190  
        
                                                          Fig. 3.18 Solvolysis 
Very little research has been done on the preparation of anhydro-D-glycal sugars, which 
are of great importance in the synthesis of complex new derivatives. 3,6-Anhydro-D-
glucal was earlier synthesized by Tucker et al. from 3,4-di-O-acetyl-6-O-tosyl-D-glucal 
using Deacidite FF IP (OH-) resin in 66% yield (Fig. 3.19).191 4,6-O-anhydro-D-glucal 
was previously reported as a byproduct (40% yield) when an equimolar amount of 
lithium aluminum hydride in THF was reacted with 6-O-tosyl-D-glucal, though the 
structure of this molecule was not fully characterized.192  
                      
                                            Fig. 3.19 Synthesis of 3,6-anhydro-D-glucal 
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The results presented describe the synthesis of 3,6-anhydro-D-glucal from 6-O-tosyl-D-
glucal using excess LiAlH4 in THF as the reagent. With this combination of reagents, an 
82% yield of anhydro-D-glycal was realized.193 The unusual chemical reactivity of the 
resulting anhydro glycal was also investigated. Also described is the synthesis of an 
unusual 1,4:3,6-dianhydrosugar via N-iodosuccinimide (NIS) addition to the 3,6-
anhydro-D-glucal. 
3.3 Results: Synthesis of 3,6-anhydro-D-glucal and a study of its chemical 
reactivity 
3,4,6-Tri-O-acetyl-D-glucal was deacetylated using Zemplen conditions to give D-glucal 
16 in 98% yield.194 The resulting D-glucal 16 was selectively tosylated at the primary 
hydroxyl using p-toluenesulfonyl chloride in a mixture of pyridine and dichloromethane.  
The 6-O-tosylated-D-glucal 17 was obtained in 56% isolated yield. Treatment of  17 with 
three equivalents of LiAlH4 in THF did not produce the anticipated 6-deoxy-D-glycal, as 
previously reported, but instead gave the 3,6-anhydro sugar 18 in 82% yield (Scheme 
3.1).195 
 
                                  Scheme 3.1 Synthesis of 3,6-anhydro-D-glucal 
Structural assignments for 18 were based on 1D and 2D 1H and 13C-NMR experiments. 
The proposed bridged structure was supported by the observation of long range 
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coupling between the vinylic proton at C2 and the bridgehead proton at C4 (W-coupling) 
in the proton NMR. In the 1H-1H-COSY (Appendix), coupling between H4 and H6 and 
H6’ was also seen, while in the 1H-NMR the H6 and H6’ peaks only appeared as broad 
doublets of doublets.  X-ray quality crystals were obtained and the structure of the 
molecule established unambiguously (Fig. 3.18), detailed information of which is given 
in the Appendix.196 
                                              
                                        Fig. 3.18 ORTEP representation of compound 18 
Compound 18 was subjected to a series of different glycal addition reactions. Treatment 
of compound 18 with NIS in the presence of methanol led to the formation of a mixture 
of β-gluco-, -manno- and -manno-2-deoxy-2-iodo-O-methylglycosides (19a, 19b, 19c) 
in a ratio of 5.2: 1.5: 1 with an overall yield of 93% (Scheme 3.2).197 None of the -gluco 
diastereomer was detected in the mixture.          
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                                     Scheme 3.2 Synthesis of 2-deoxy-2-iodo-O-methylglycosides 
Treatment of 18 with thiophenol in the presence of a catalytic amount of ceric (IV) 
ammonium nitrate (CAN) gave a mixture of α- and β-2-deoxy sugars (20a, 20b) in a 
ratio 1.85:1 with a 65% yield. Also formed in the reaction was an α-, β-mixture of the 
Ferrier rearranged adducts (21a, 21b) with a 35% yield in a ratio of 2.5:1, formed upon 
the breakdown of the anhydride ring (Scheme 3.3).198 
                                                                      
                       Scheme 3.3 Addition of thiophenol to 18 in the presence and absence of CAN 
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When the anhydro sugar 18 was reacted with thiophenol and a catalytic amount of ceric  
(IV) ammonium nitrate in the presence of sodium iodide, a reagent known to enhance -
selectivity, a mixture of α- and β-2-deoxy sugars (20a, 20b) was again obtained in this 
reaction (34%), but only the α-adduct 21a from the Ferrier rearrangement was isolated 
(65%) (Scheme 3.3).199     
Because of the success of the NIS addition with methanol, attempts were made to 
synthesize disaccharides from the anhydro sugar donor. Compound 18 was treated with 
an equimolar amount of 1,2:3,4-di-O-isopropylidine-D-galactopyranose (DIPG) in the 
presence of N-iodosuccinimide to give 2-deoxy-2-iodo-1,4:3,6-dianhydride 22 as the 
major product (48%). An inseparable mixture of 2-deoxy-2-iodo sugars (23a, 23b, 23c) 
was also formed in low yield, and residual starting materials were isolated (~20%) 
(Scheme 3.4). When the same reaction was repeated in the absence of 1,2:3,4-di-O-
isopropylidine-D-galactopyranose and in the presence of 4 Ǻ molecular sieves, 22 was 
obtained in a much higher yield of 76% (Scheme 3.5). 
 
                      Scheme 3.4 Synthesis of 1,4:3,6-dianhydride 22 from 18 in the presence of DIPG 
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                       Scheme 3.5 Synthesis of 1,4:3,6-dianhydride 22 from 18 in the absence of DIPG 
3.4 Summary 
In summary, good yields of 3,6-anhydro-D-glucal  18 have been obtained from 6-O-
tosyl-D-glucal 17 via reaction with excess lithium aluminum hydride. The resulting 
anhydro glycal was studied under a variety of reaction conditions. Iodoglycosylation of 
18 with methanol gave good yields of a mixture of 2-deoxy-2-iodomethylglycosides 19a-
c, but attempts to use the primary hydroxyl sugar donor 1,2:3,4-diisopropylidine-D- 
galactopyranose gave the dianhydro sugar 22 and iodohydrins 23a-c. These observed 
products may result due to the steric hindrance present in the anhydro glycal reactant or 
in the transition state for the reaction. Alternatively, unfavorable dipole-dipole 
interactions in the transition state for the sugar nucleophile approaching the glycal 
double bond may be responsible for the observed products. β-Anomers were favored 
over α-anomers by a ratio of ~ 4:1. Furthermore, the formation of 22 is favored because 
the intramolecular attack by the bridgehead hydroxyl group is anticipated to be faster 
entropically than is the attack by the solvated nucleophiles. The small methanol 
nucleophile and adventitious water can more easily access the double bond and 
mixtures of product resulted from their attack. In those cases where the DIPG was 
excluded and freshly powdered and activated 4 Ao molecular sieves were added, only 
the dianhydro sugar 22 was obtained.  Further reactions with 18 are ongoing. 
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4.1 Experimental 
General Methods. 
Melting points (mp) were recorded on a Mel-Temp melting point apparatus (Laboratory Devices, 
Inc., USA) and are uncorrected. Proton nuclear magnetic resonance (1H NMR) spectra were 
recorded on a Varian Inova (500 MHz) spectrometer. NMR samples were dissolved in CDCl3, 
and chemical shifts were reported in ppm relative to the residual non-deuterated solvent (CHCl3 
as δ = 7.26 ppm). 1H NMR data are reported as follows: chemical shift, integration, multiplicity 
(s = singlet; d = doublet; d, d = doublet of a doublet; d, d, d = doublet of a doublet of a doublet; 
m = multiplet), coupling constant, and assignment. 13C NMR spectra were recorded on a Varian 
Inova (125 MHz) spectrometer. The samples were dissolved in CDCl3, and chemical shifts are 
reported in ppm relative to the solvent (CDCl3 as δ = 77.0 ppm). 1H and 13C NMR spectra were 
measured at room temperature and the chemical shifts are reported in parts per million, unless 
otherwise noted. 1H NMR assignments were done using gCOSY and 13C NMR assignments were 
done using gHMQC. Elemental analysis was performed at Robertson Microlit Laboratories Inc., 
Ledgewood, NJ. High resolution and low resolution mass spectra (HRMS and LRMS) were 
obtained at the Mass Spectrometry Lab, University of Illinois, Champaign-Urbana, IL and are 
reported in m/z (electrospray ionization). X-ray crystallographic data for compound 2 was 
deposited at the Cambridge Crystallographic Data Center (CCDC); deposition number CCDC 
988697.20 Reactions were monitored by thin-layer chromatography (TLC) on 0.25 mm silica gel 
coated aluminum sheet 60 F254 (Analtech, # 157017). Silica gel (particle size 40-63 µm, 230-400 
mesh Silicycle Siliflash P60) was used for flash column chromatography. Preparative thin-layer 
chromatographic separations were carried out on 2000 µm silica gel coated glass plate 60 F254 
(Analtech). Rotary evaporation was performed using a Buchi R-114 rotary evaporator. Unless 
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otherwise noted, non-aqueous reactions were carried out in oven-dried (125 oC) glassware under 
nitrogen. Dry CH3CN, THF and methanol were purchased from Pharmco-Aaper products, Inc. 
All other commercially available reagents were used as received.   
Thiophenyl-2,3,4,6-tetra-O-acetyl-β-D-galactopyranose (2): To a solution of penta-O-acetyl-
β-D-galactopyranose (9 g, 23.056 mmol) in 30 mL of anhydrous CHCl3 in a 100 mL r. b. f. was 
added 2.84 mL of thiophenol (3.048 g, 1.2 eq, 27.667 mmol) under an atmosphere of N2. To the 
mixture was then added 7.3 mL of BF3. Et2O and stirred at room temperature for 3 days. The 
reaction was then terminated by diluting with excess CHCl3, followed by washings with 
saturated NaHCO3 soln. (2 x 50 mL) and 10% w/v NaOH soln. (2 x 50 mL). The organic extract 
was dried over anhydrous Na2SO4 and concentrated in vacuo to yield the crude product. The 
product was purified by flash column chromatography using 30%, 40% and 50% EtOAc in 
hexanes to give 9.809 g (97%) of the desired compound as a white solid. Rf (1:1 EtOAc/ 
hexanes): 0.66; 1H NMR (500 MHz, CDCl3) δ 7.49-7.51 (m, 2H, Ar), 7.26-7.31 (m, 3H, Ar), 
5.41 (dd, 1H, J3,4 = 3.4 Hz, J4,5 = 1 Hz, H-4), 5.23 (dd, 1H, J1,2 = 10 Hz, J2,3 = 9.8 Hz, H-2), 5.04 
(dd, J2,3 = 10.2 Hz, J3,4 = 3.4 Hz, H-3), 4.71 (d, 1H, J1,2 = 10.3, H-1), 4.18 (dd, 1H, J6,6’ = 11.45, 
J5,6’ = 6.8, H-6’), 4.1 (dd, 1H, J5,6 = 5.8, J6,6’ = 12.1, H-6), 3.93-3.95 (m, 1H, H-5); 13C NMR (125 
MHz, CDCl3) δ 170.36, 170.19, 170.04, 169.42 (C=O, OAc), 132.57, 132.47, 128.89, 128.16 
(CH, Ar), 86.6 (C-1), 74.42 (C-5), 72 (C-2), 67.26, 67.22 (C-3, C-4), 61.63 (C-6), 20.85, 20.66, 
20.63, 20.58 (CH, OAc). 
Thiophenyl-β-D-galactopyranose (3): To a solution of the above obtained thiophenyl adduct 
(8.33 g, 18.93 mmol) in 30 mL of anhydrous CH3OH was added 0.1 eq of 5% NaOCH3 in 
CH3OH solution. The mixture was stirred at room temperature for 4 h under an atmosphere of 
N2. The reaction upon reaching completion was rotary evaporated to get rid of CH3OH. The 
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resulting syrupy product was then dried under high vacuum to give 5.1589 g (100%) of the 
desired deacetylated product as a yellowish-white powder. Rf (5% CH3OH/CHCl3): 0.03; 
1H 
NMR (500 MHz, CDCl3) δ 7.43-7.45 (d, 2H, JAr,Ar = 6.3 Hz, Ar), 7.27-7.31 (m, 2H, Ar), 7.18-
7.21 (m, 2H, Ar), 4.72 (s, 4H, -OH), 4.57 (d, 1H, J1,2 = 9.8 Hz, H-1), 3.71 (d, 1H, J3,4 = 3.4 Hz, 
H-3), 3.46-3.53 (m, 3H, H-5, 6, 6’), 3.42 (d, 1H, J1,2 = 9.3 Hz, H-2), 3.35 (dd, 1H, J3,4 = 3.4 Hz, 
J4,5 = 9 Hz, H-4);
 13C NMR (125 MHz, CDCl3) δ 140.76, 134.49, 134, 131.3 (CH, Ar), 92.95 (C-
1), 84.37 (C-5), 79.9 (C-2), 74.46 (C-6), 73.54 (C-3), 65.77 (C-4). 
Thiophenyl-4,6-O-benzylidene-β-D-galactopyranose (4): Into an oven-dried 250 mL r. b. f. 
was taken ZnCl2 (14.27 g, 5 eq) and flame fused under an atmosphere of N2 to make it totally 
anhydrous. To the cooled r. b. f. containing fused ZnCl2 was added benzaldehyde (12.21 g, 5.5 
eq) and thiophenyl-β-D-galactopyranose (5.69 g, 20.945 mmol) and the mixture was stirred 
under an atmosphere of N2 overnight. Additionally, 15 mL of benzaldehyde was added to the 
mixture, for it being the only solvent used in this reaction. When the reaction was found to have 
almost reached completion, it was diluted with excess CHCl3 and washed with saturated 
NaHCO3 solution (2 x 50 mL). The organic layer was separated and dried over anhydrous 
Na2SO4, and evaporated in vacuo to get a crude viscous oily mass. The crude product was 
purified by flash column chromatography using gradient dilution technique (40%, 50%, 60%, 
70%, 80% and 90% EtOAc in hexanes) to result in 5.2 g (70%) of the desired benzylidene 
adduct as a solid white powder. Rf (80% EtOAc/hexanes): 0.245; 
1H NMR (500 MHz, CDCl3) δ 
8.12-8.14 (m, 2H, Ar), 7.69-7.71 (m, 2H, Ar), 7.61-7.65 (m, 1H, Ar), 7.48-7.51 (m, 1H, Ar), 
7.41-7.43 (m, 2H, Ar), 7.37-7.4 (m, 2H, Ar), 5.53 (s, 1H, Bn-Ar), 4.53 (dd, 1H, J1,2 = 4.4 Hz, J1,3 
= 2.2 Hz, H-1), 4.4 (dd, 1H, J6,6’ = 12.7 Hz, J5,6’ = 1.5 Hz, H-6), 4.23 (d, 1H, J3,4 = 1.5 Hz, H-4), 
4.04 (dd, 1H, J6,6’ = 12.45 Hz, J5,6’ = 2 Hz, H-6’), 3.71-3.75 (m, 2H, H-2, 5), 3.55 (d, 1H, J3,4 = 1 
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Hz); 13C NMR (125 MHz, CDCl3) δ 137.6, 133.7, 133.69, 130.18, 129.34, 128.93, 128.48, 
128.23, 128.18, 126.54 (CH, Ar), 101.4 (Bn-Ar), 87 (C-1), 75.4 (C-4), 73.8 (C-5), 70.06 (C-3), 
69.28 (C-6), 68.8 (C-2). 
Thiophenyl-3-O-benzoyl-4,6-O-benzylidene-β-D-galactopyranose (5a): 4.834 g (13.4 eq) of 
thiophenyl-4,6-O-benzylidene-β-D-galactopyranose was taken into an oven-dried 250 mL screw-
cap tube and to it was added 60 mL of anhydrous toluene. The sealed tube was heated to 117 oC 
upon thorough stirring for three days in the presence of 4 Ao molecular sieves. After three days, 
the tube was cooled to r.t., filtered and evaporated in vacuo to yield a syrupy liquid. To the 
syrupy liquid was added 15 mL of anhydrous CHCl3 and an ice-cooled solution of benzoyl 
chloride (1.977 g, 1.05 eq) in 15 mL of anhydrous CHCl3. The mixture was stirred for 2 h at r. t. 
after which it was evaporated in vacuo to yield 7.838 g of the crude product as a yellowish-
orange solid. Gradient dilution technique (30%, 40%, 50% and 60% EtOAc in hexanes) was 
used to purify the crude by flash column chromatography to yield 1.928 g (31%) of the desired 
product as an oily colourless liquid. 0.71 g of a mixture of the 2-O-benzyl- and the 3-O-benzyl- 
adducts was also obtained. Rf (30% EtOAc/hexanes): 0.327 (Rf of the 2-O-benzyl adduct: 0.39); 
1H NMR (500 MHz, CDCl3) δ 8.03-8.05 (m. 2H, Ar), 7.72-7.7 (m, 2H, Ar), 7.53-7.56 (m, 1H, 
Ar), 7.38-7.42 (m, 5H, Ar), 7.31-7.38 (m, 4H, Ar), 7.25-7.28 (m, 1H, Ar), 5.51 (s, 1H, Bn-Ar), 
5.19 (dd, 1H, J2,3 = 11.3 Hz, J3,4 = 3.1 Hz, H-3), 4.68 (d, 1H, J1,2 = 9.5 Hz, H-1), 4.51 (s, 1H, H-
4), 4.42 (d, 1H, J6,6’ = 12.3 Hz, H-6), 4.06-4.18 (m, 2H, H-2, 6’), 3.7 (s, 1H, H-5); 13C NMR (125 
MHz, CDCl3) δ 165.9 (-CO-Ar), 137.3, 133, 130, 129.9, 128, 127.8, 126.3 (CH, Ar), 108.9 (Bn-
Ar), 93.1 (C-1), 79.3 (C-4), 79.2 (C-5), 74.4 (C-3), 71.2 (C-2), 67.8 (C-6); LRMS (ESI): Calcd 
C26H24O6S: 464.1. Found for (M+Na)
+: 487.1.  
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Thiophenyl-2-O-acetyl-3-O-benzoyl-4,6-O-benzylidene-β-D-galactopyranose (6): To a 
solution of the above obtained thiophenyl-3-O-benzoyl-4,6-O-benzylidene-β-D-galactopyranose 
(2 g, 4.31 mmol) in 10 mL of N, N, N-triethylamine was added N, N-dimethylaminopyridine 
(38.67 mg, 0.08 eq) and stirred at 0 oC for 30 min. To the ice-cold solution was added 507.54 mg 
(1.5 eq) of acetyl chloride drop-wise and the reaction was vigorously stirred at 0 oC initially and 
at r.t. for 2 days. The reaction was terminated by diluting with CH2Cl2 (50 mL) and, by washing 
with 2 N HCl (2 x 25 mL) and saturated NaHCO3 solution (2 x 25 mL). The organic layer was 
dried over anhydrous MgSO4 and evaporate in vacuo to give 2.44 g of the crude product as an 
orange fluffy solid. Purification was carried out by flash column chromatography using 30% 
EtOAc in hexanes as the eluent. 1.3 g (60%) of the desired product was obtained as a yellow oily 
liquid. Rf (30% EtOAc/hexanes): 0.44; 
1H NMR (500 MHz, CDCl3) δ 7.99-7.97 (m, 2H, Ar), 
7.63-7.64 (m, 2H, Ar), 7.52-7.55 (m, 1H, Ar), 7.31-7.41 (m, 8H, Ar), 5,56 (d, 1H, J2,3 = 9.9 Hz, 
H-2), 5.48 (s, 1H, Bn-Ar), 5.2 (dd, 1H, J1,2 = 9.9 Hz, J2,3 = 9.8 Hz, H-3), 4.79 (d, 1H, J1,2 = 9.8 
Hz, H-1), 4.54 (s, 1H, H-4), 4.42 (d, 1H, J6,6’ = 12.4 Hz, H-6), 4.06 (d, 1H, J6,6’ = 12.4 Hz, H-6’), 
3.69 (s, 1H, H-5), 2.01 (s, 3H, -CO-CH3); 
13C NMR (125 MHz, CDCl3) δ 170.1 (-CO-CH3), 
165.9 (-CO-Ar), 137.3, 133.9, 133, 130, 129.3, 128.6, 127.8, 125 (CH, Ar), 108.9 (Bn-Ar), 89.8 
(C-1), 79.6 (C-4), 78.9 (C-5), 73.8 (C-3), 70.4 (C-2), 67.8 (C-6), 21.0 (CH3); LRMS (ESI): Calcd 
C28H26O7S: 506.1. Found for (M+NH4)
+: 524.2.  
Thiophenyl-2-O-acetyl-3-O-benzoyl-β-D-galactopyranose (7a): To a solution of thiophenyl-2-
O-acetyl-3-O-benzoyl-4,6-O-benzylidene-β-D-galactopyranose in anhydrous dichloromethane 
(20 mL) at -15 oC was added drop-wise a mixture of 20% v/v trifluoroacetic acid (880 mg, 6 eq) 
in CH2Cl2. The mixture was brought to r.t. and stirred overnight in an atmosphere of N2. The 
reaction was terminated by the addition of excess CH2Cl2 (30 mL), and washed with saturated 
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NaHCO3 solution (2 x 25 mL) and water (2 x 25 mL). The organic layer was separated and dried 
over anhydrous Na2SO4, and evaporated in vacuo to yield 820 mg of the crude 4,6-diol sugar. 
The compound was purified by flash column chromatography by gradient dilution method (30%, 
40%, 50% and 60% EtOAc in hexanes) to yield 244 mg (45%) of the pure product. Rf (30% 
EtOAc/hexanes): 0.137; 1H NMR (500 MHz, CDCl3) δ 7.98-8.0 (m, 3H, Ar), 7.93-7.95 (m, 2H, 
Ar), 7.52-7.58 (m, 3H, Ar), 7.44-7.45 (m, 2H, Ar), 5.58 (d, 1H, J1,2 = 9.9 Hz, H-2), 5.22 (dd, 1H, 
J2,3 = 9.9 Hz, J3,4 = 3.1 Hz, H-3), 5.07 (d, 1H, J1,2 = 10.1 Hz, H-1), 4.42 (d, 1H, J3,4 = 3.1 Hz, H-
4), 4.06 (m, 1H, H-5), 3.84 (m, 2H, H-6, 6’), 1.97 (s, 3H, -CO-CH3); 13C NMR (125 MHz, 
CDCl3) δ 170.1 (-CO-CH3), 165.9 (-CO-Ar),133.9, 133, 129.3, 129.3, 129.9, 128, 125.1 (CH, 
Ar), 89.8 (C-1), 86.3 (C-5), 73.3 (C-3), 70.1 (C-2), 67.7 (C-4), 61.2 (C-6), 21.0 (CH3); HRMS 
(ESI): Calcd C21H23O7S for (M+H)
+: 419.1165. Found: 419.1173. 
Thiophenyl-2-O-acetyl-3-O-benzoyl-4,6-O-pyruvate-β-D-galactopyranose (7): To a 
suspension of thiophenyl-2-O-acetyl-3-O-benzoyl-β-D-galactopyranose (10 mg, 0.024 mmol) in 
methyl pyruvate (57.5 mg, 23.5 eq) was added BF3-Etherate drop-wise. The mixture was allowed 
to stir at r.t. overnight in an atmosphere of N2. The reaction was terminated by the addition of 1 
mL of N, N, N-triethylamine to neutralize the acid. The mixture was poured into 25 mL of 
saturate NaHCO3 solution and extracted with CH2Cl2 (2 x 50 mL). The organic layer was dried 
over anhydrous Na2SO4 and evaporated in vivo to give the desired pyruvate adduct in its crude 
form. The crude product was purified by preparatory TLC using 50% EtOAc in hexanes mixture 
as the eluent (with trace amounts of N, N, N-triethylamine) to give 10 mg (80%) of the pyruvate 
adduct. Rf (50% EtOAc/hexanes): 0.77; 
1H NMR (500 MHz, CDCl3) δ 7.97-8.01 (m, 3H, Ar), 
7.92-7.95 (m, 2H, Ar), 7.5-7.54 (m, 2H, Ar), 7.44-7.49 (m, 3H, Ar), 5.45-5.47 (m, 1H, H-2), 
5.29-5.34 (m, 1H, H-3), 5.08 (dd, 1H, J1,2 = 10 Hz, J1,3 = 2.8 Hz, H-1), 4.63 (dd, 1H, J3,4 = 7.8 Hz, 
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J4,5 = 3.4, H-4), 4.09-4.1 (m, 1H, H-6), 4.06-4.07 (m, 1H, H-6’), 3.89-3.9 (m, 1H, H-5), 3.27 (s, 
3H, -OCH3), 2.01 (s, 3H, -CO-CH3), 1.63 (s, 3H, CH3); 
13C NMR (125 MHz, CDCl3) δ 170.2 (-
CO-CH3), 168.9 (-CO-OCH3), 165.9 (-CO-Ar) 133.9, 133, 130.1, 129.3, 128.6, 125.1 (Ar), 
114.9 (Pyr), 89.8 (C-1), 79.1 (C-4), 78.9 (C-5), 73.8 (C-3), 70.4 (C-2), 65.1 (C-6), 52.5 (-CO-
OCH3), 25.5 (CH3), 21.0 (-CO-CH3); HRMS (ESI): Calcd C25H26O9NaS for (M+Na)
+: 525.1195. 
Found: 525.1205. 
4-O-tert-butyldimethylsilyl-cyclohexanol (12a): To a solution of cis/trans mixture of 1, 4-
cyclohexanediol (200 mg, 1.72 mmol) in N, N-dimethylformamide (5 mL) was added 2.5 eq of 
imidazole (292. 7 mg) and the mixture was stirred at r.t. 30 min. To the solution was added tert-
butyldimethylsilyl chloride (1.25 eq, 292.7 mg) and the mixture was stirred for 3 days in an 
atmosphere of N2. At the end of the third day, the mixture was diluted with excess CH2Cl2 (30 
mL), washed with water (5 x 25 mL) and saturated NaCl (aq) solution (1 x 25 mL). The organic 
layer was dried over anhydrous Na2SO4 and then evaporated in vacuo to give 276 mg of the 
crude product. Purification was done by flash column chromatography using 50% EtOAc in 
hexanes as the eluent which gave 196 mg (50%) of the product. Rf (50% EtOAc/hexanes): 0.87; 
1H NMR (500 MHz, CDCl3) δ 3.79-3.83 (m, 1H, H-1), 3.65-3.70 (m, 1H, H-4), 1.6-1.77 (m, 6H, 
H-2a, 2e, 3e, 5e, 6a, 6e), 1.46-1.5 (m, 1H, H-3a), 1.28-1.32 (m, 1H, H-5a), 0.89 (s, 9H, t-butyl), 
0.04 (s, 6H, CH3); 
13C NMR (125 MHz, CDCl3) δ 78.1 (C-4), 69.7 (C-1), 32.1 (C-2, 6), 31.3 (C-
3, 5), 30.9 (-CCH3, t-butyl), 25.9 (-CCH3, t-butyl), -2.0 (CH3). 
2-Phthalimido-per-O-acetyl-β-D-glucopyranose (9): To a solution of NaOCH3 (2 g, 37.037 
mmol) in CH3OH (60 mL) in an oven dried 250 mL r. b. f. was added glucosamine HCl (10 g, 
46.3 mmol) and the mixture was stirred at r. t. in an atmosphere of N2 for 30 min. 6.852 g of 
phthalic anhydride (1 eq) was added to the mixture and was stirred at r. t. for 20 h. The reaction 
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was terminated by evaporating the solvent in vacuo. To the solid residue obtained was added 60 
mL of acetic anhydride and 50 mL of pyridine and the mixture was stirred at r. t. for 42 h for per-
acetylating the sugar. The reaction was terminated by adding 100 g of ice and stirring the 
mixture for 30 min. The mixture was extracted with CH2Cl2 (2 x 150 mL). The combined 
organic extracts were washed with 3M H2SO4 solution (4 x 100 mL), water (2 x 150 mL), 
saturated NaHCO3 and water (2 x 150 mL) again sequentially. The organic layer was dried over 
anhydrous Na2SO4, filtered and concentrated to dryness in vacuo to give 18.42 g of a yellow 
fluffy solid. Flash column chromatography of the crude product by gradient dilution method 
(40%, 50% and 60% EtOAc/hexanes) gave 6.54 g (30%) of the desired pure product. Rf (40% 
EtOAc/hexanes): 0.32; 1H NMR (500 MHz, CDCl3) δ 7.85-7.87 (m, 2H, Ar), 7.73-7.76 (m, 2H, 
Ar), 6.51 (d, 1H, J1,2 = 8.9 Hz, H-1), 5.88 (dd, 1H, J2,3 = 10.6 Hz, J3,4 = 9.1 Hz, H-3), 5.21 (d, 1H, 
J3,4 = 10 Hz, H-4), 4.46 (dd, 1H, J2,3 = 10.6 Hz, J1,2 = 8.9 Hz, H-2), 4.36 (dd, 1H, J6,6’ = 12.4 Hz, 
J5,6 = 4.4 Hz, H-6), 4.11-4.14 (m, 1H, H-6’), 4.01-4.04 (m, 1H, H-5), 2.11 (s, 3H, -CO-CH3), 
2.04 (s, 3H, -CO-CH3), 2.00 (s, 3H, -CO-CH3), 1.86 (s, 3H, -CO-CH3); 
13C NMR (125 MHz, 
CDCl3) δ 172.9, 170.2 (-CO-CH3), 167.6 (-CO-N-), 132.2, 123.7 (Ar), 93.4 (C-1), 74.7 (C-5), 
70.8 (C-3), 69.9 (C-4), 61.9 (C-2), 62.4 (C-6), 21.0 (-CO-CH3). 
Thioethyl-2-phthalimido-3,4,6-tri-O-acetyl-β-D-glucopyranose (10): To a solution of 2-
phthalimido-per-O-acetyl-β-D-glucopyranose (1.5 g, 3.14 mmol) in 30 mL of CHCl3 in a clean 
oven dried 100 mL r. b. f. was added ethanethiol (1.2 eq, 234 mg) and the mixture was stirred at 
r. t. for 15 min in an atmosphere of N2. To the mixture was added BF3. Et2O drop-wise and the 
mixture was stirred at r. t. for 4 days. When TLC showed that the reaction reached completion, 
the mixture was diluted with 100 mL of CH2Cl2, washed with saturated NaHCO3 solution (2 x 
150 mL) and 10% w/v NaOH (aq) solution (1 x 100 mL). The combined organic layers were 
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dried over anhydrous Na2SO4 and concentrated to dryness in vacuo to give 1.35 g of a red fluffy 
solid. The crude product was purified by flash column chromatography, using 50% EtOAc in 
hexanes as the eluent, to yield 1.188 g (79%) of the pure product. Rf (50% EtOAc/hexanes): 
0.49; 1H NMR (500 MHz, CDCl3) δ 7.85-7.86 (m, 2H, Ar), 7.73-7.76 (m, 2H, Ar), 5.82 (dd, 1H, 
J2,3 = 10.3 Hz, J3,4 = 9.2 Hz, H-3), 5.48 (d, 1H, J1,2 = 10.7 Hz, H-1), 5.17 (dd, 1H, J4,5 = 10.1 Hz, 
J3,4 = 9.2 Hz, H-4), 4.39 (d, 1H, J1,2 = 10.4 Hz, H-2), 4.3 (dd, 1H, J6,6’ = 12.4 Hz, J5,6 = 4.9 Hz, H-
6), 4.17 (dd, 1H, J6,6’ = 12.3 Hz, J5,6’ = 2.3 Hz, H-6’), 3.89 (ddd, 1H, J4,5 = 10.25 Hz, J5,6 = 4.85 
Hz, J5,6’ = 2.4 Hz, H-5), 2.62-2.71 (m, 2H, -S-CH2-CH3), 2.10 (s, 3H, -CO-CH3), 2.03 (s, 3H, -
CO-CH3), 1.86 (s, 3H, -CO-CH3), 1.21 (t, 3H, JCH2,CH3 = 7.3 Hz, -S-CH2-CH3); 
13C NMR (125 
MHz, CDCl3) δ 170.2 (-CO-CH3), 169.6 (-CO-N-), 132.2, 123.8 (Ar), 81.3 (C-1), 76.12 (C-5), 
71.7 (C-3), 69.1 (C-4), 62.48 (C-6), 53.86 (C-2), 24.52 (-S-CH2-CH3), 20.91, 20.77, 20.6 (-CO-
CH3), 15.04 (-S-CH2-CH3). 
(4-tert-butyldimethylsilyl-cyclohexyl)-2-phthalimido-3,4,6-tri-O-acetyl-β-D-glucopyranose 
(13): Into a clean oven dried 25 mL r. b. f. was taken 575 mg (1.2 mmol) of thioethyl-2-
phthalimido-3,4,6-tri-O-acetyl-β-D-glucopyranose, To it was added 15 mL anhydrous CH2Cl2 
and the mixture was cooled to -78 oC (acetone/dry ice) upon stirring in an inert atmosphere. To 
the mixture was added N-iodosuccinimide (2.5 eq, 675 mg) and stirred at -78 oC for 30 min. 
Keeping the temperature constant, 10 µL (0.05 eq) of trimethylsilyl trifluoromethanesulfonate 
(TMSOTf) was added drop-wise to the mixture upon vigorous stirring. To the mixture was added 
drop-wise a solution of 4-O-tert-butyldimethylsilyl-cyclohexanol (1.2 eq, 331.2 mg) in CH2Cl2 
(2 mL) and the reaction was stirred at -78 oC for 90 min. The reaction was terminated and the 
mixture was diluted with excess CH2Cl2 (100 mL) and washed with saturated NaHCO3 solution 
(1 x 50 mL). The organic layer was dried over anhydrous MgSO4, filtered and concentrated to 
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dryness in vacuo to yield a gram of the crude product as a dark brown oily syrup. Purification 
was done by flash column chromatography using gradient dilution (30%, 40%, 50%, 60%, 70%, 
80%, 90% EtOAc in hexanes) which yielded 503 mg (65%) of the product as a pale yellow oily 
syrup. Rf (60% EtOAc/hexanes): 0.83; 
1H NMR (500 MHz, CDCl3) δ 7.84-7.87 (m, 2H, Ar), 
7.71-7.75 (m, 2H, Ar), 5.76-5.83 (m, 1H, H-3), 5.44 (dd, 1H, J1,2 = 8.75 Hz, J1,3 = 2.4 Hz, H-1), 
5.13-5.18 (m, 1H, H-4), 4.28-4.35 (m, 2H, H-2, 6), 4.16 (d, 1H, J6,6’ = 12.2 Hz, H-6’) 3.84-3.87 
(m, 1H, H-5), 3.59-3.68 (m, 1H, Cyclohexyl-H-1), 3.49-3.53 (m, 1H, Cyclohexyl-H-4), 2.11 (s, 
3H, -CO-CH3), 2.03 (s, 3H, -CO-CH3), 1.86 (s, 3H, -CO-CH3), 1.68-1.8 (m, 2H, Cyclohexyl-H-
2e, 6e), 1.24-1.40 (m, 4H, Cyclohexyl-H-3e, 2a, 5e, 6a), 1.19-1.40 (m, 1H, Cyclohexyl-H-3a), 0.83 
(s, 5H, H-t-butyl), 0.74 (s, 4H, H-t-butyl), -0.04 (s, 3H, CH3), -0.08 (s, 3H, CH3), -0.12 (s, 3H, 
CH3); 
13C NMR (125 MHz, CDCl3) δ 172.96, 171.06 (-CO-CH3), 169.84 (-CO-N-), 134.57, 
123.92 (Ar), 97.05 (C-1), 72.11 (C-5), 71.21 (C-3), 69.59 (C-4), 62.60 (C-6), 49.66 (C-2), 31.13 
(-CCH3, t-butyl), 26.15, 26.02 (-CCH3, t-butyl), 21.13, 21, 20.82 (-CO-CH3), -4.43 (CH3); 
LRMS (ESI): Calcd C32H45NO11Si: 647.3. Found for (M+H)
+: 648.3.  
Cyclohexyl-2-phthalimido-3,4,6-tri-O-acetyl-β-D-glucopyranose (14): Into a clean oven dried 
10 mL r. b. f. was taken 25 mg (0.052 mmol) of thioethyl-2-phthalimido-3,4,6-tri-O-acetyl-β-D-
glucopyranose, To it was added 5 mL anhydrous CH2Cl2 and the mixture was cooled to -78 
oC 
upon stirring in an inert atmosphere. To the mixture was added N-iodosuccinimide (2.5 eq, 29.34 
mg) and stirred at -78 oC (acetone/dry ice) for 30 min. Keeping the temperature constant, 0.46 
µL (0.05 eq) of trimethylsilyl trifluoromethanesulfonate (TMSOTf) was added drop-wise to the 
mixture upon vigorous stirring. To the mixture was added drop-wise a solution of 4-O-tert-
butyldimethylsilyl-cyclohexanol (1.2 eq, 14.35 mg) in CH2Cl2 (1 mL) and the reaction was 
stirred at -78 oC for 7 h. The reaction was terminated and the mixture was diluted with CH2Cl2 
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(25 mL) and washed with saturated NaHCO3 solution (1 x 25 mL). The organic layer was dried 
over anhydrous MgSO4, filtered and concentrated to dryness in vacuo to yield the crude product 
as a orange-brown oily syrup. Purification was done by preparatory TLC technique using 80% 
EtOAc in hexanes as the solvent which yielded 32 mg (95%) of the product as a yellowish oily 
syrup. Rf (60% EtOAc/hexanes): 0.157;  
1H NMR (500 MHz, CDCl3) δ 7.84-7.86 (m, 2H, Ar), 
7.72-7.76 (m, 2H, Ar), 5.75-5.82 (m, 1H, H-3), 5.44 (dd, 1H, J1,2 = 8.4 Hz, J1,3 = 6.4 Hz, H-1), 
5.15-5.19 (m, 1H, H-4), 4.28-4.36 (m, 2H, H-2, 6), 4.16 (m, 1H, J6,6’ = 10.8 Hz, H-6’), 3.85-3.88 
(m, 1H, H-5), 3.73-3.77 (m, 1H, Cyclohexyl-H-1), 3.56-3.65 (m, 1H, Cyclohexyl-H-4), 2.11 (s, 
3H, -CO-CH3), 2.03 (s, 3H, -CO-CH3), 1.95-1.98 (m, 1H, Cyclohexyl-H-2
e), 1.86 (s, 3H, -CO-
CH3), 1.69-1.76 (m, 1H, Cyclohexyl-H-6
e), 1.33-1.43 (m, 2H, Cyclohexyl-H-3e, 5e), 1.17-1.31 
(m, 2H, Cyclohexyl-H-3a, 5a); 13C NMR (125 MHz, CDCl3) δ 170.73, 170.22 (-CO-CH3), 
169.51, 165.52 (-CO-N-), 134.35, 131.38, 123.6 (Ar), 96.85 (C-1), 76.86 (Cyclohexyl-C-1), 
71.78 (C-3, 5), 70.88 (C-4), 69.19 (Cyclohexyl-C-4), 62.23 (C-6), 54.86 (C-2), 30.47, 30.06 
(Cyclohexyl-C-2, 3, 5, 6), 20.78, 20.65, 20.46 (-CO-CH3). LRMS (ESI): Calcd C26H31NO11: 
533.2. Found for (M+H)+: 534.2.  
(Cyclohexyl-2-phthalimido-3,4,6-tri-O-acetyl-β-D-glucopyranosyl)-2-O-acetyl-3-O-benzoyl-
4,6-O-pyruvate-β-D-galactopyranose (15): 61.279 mg (1.3 eq) of thiophenyl-2-O-acetyl-3-O-
benzoyl-4,6-O-pyruvate-β-D-galactopyranose and 5 mL of anhydrous CH2Cl2 were taken in a 
clean oven tried 10 mL r. b. f. and the mixture was stirred at -42 oC (CH3CN/dry ice) in an inert 
atmosphere for 15 min. 68.625 mg (2.5 eq) of N-iodosuccinimide was added to the mixture and  
stirred for 30 min at -42 oC. Keeping the temperature constant, 1.3 µL of TMSOTf (0.05 eq) was 
added to the mixture drop-wise upon vigorous stirring. To the mixture was added a solution of 
cyclohexyl-2-phthalimido-3,4,6-tri-O-acetyl-β-D-glucopyranose (50 mg, 0.0939 mmol) in 
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anhydrous CH2Cl2 (1 mL) and the reaction was run at -42 
oC for 3 h upon continuous stirring. 
The reaction was terminated by adding excess CH2Cl2 (40 mL), washed with saturated NaHCO3 
solution (1 x 50 mL) and 10% w/v Na2S2O3 solution (1 x 50 mL). The organic layer was 
separated, dried over anhydrous MgSO4, filtered and concentrated to dryness in vacuo to yield 
135 mg of the crude product as an orange oily syrup. Purification was done by preparatory TLC 
technique using 60 % EtOAc in hexanes as the solvent, which gave 50 mg (57.6%) of the 
product as an off white coloured solid. 1H NMR (500 MHz, CDCl3) δ 7.99-8.04 (m, 2H, Ar), 
7.91-7.96 (m, 1H, Ar), 7.83-7.88 (m, 1H, Ar), 7.73-7.77 (m, 1H, Ar), 7.49-7.54 (m, 1H, Ar), 
7.36-7.41 (m, 1H, Ar), 7.35-7.41 (m, 2H, Ar), 5.73-5.80 (m, 1H, Hglu-1), 5.62-5.66 (m, 1H, 
Hgal-1), 5.36-5.46 (m, 2H, Hglu-3, Hgal-2), 5.13-5.19 (m, 1H, Hgal-3), 4.48-4.60 (m, 1H, Hglu-4), 
4.26-4.34 (m, 2H, Hgal-4, Hglu-2), 4.10-4.27 (m, 2H, Hglu-5, 6), 3.93-4.08 (m, 2H, Hglu-6’, Hgal-6), 
3.80-3.90 (m, 2H, Hgal-6’, Cyclohexyl-H-1), 3.73-3.78 (m, 1H, Hgal-5), 3.61-3.7 (m, 3H, -OCH3), 
3.41-3.53 (m, 1H, Cyclohexyl-H-4), 2.11 (s, 1H, -CO-CH3), 2.10 (s, 1H, -CO-CH3), 2.06 (s, 1H, 
-CO-CH3), 1.87 (s, 1H, -CO-CH3), 1.86 (s, 1H, -CO-CH3), 1.85 (s, 1H, -CO-CH3), 1.65-1.83 (m, 
4H, Cyclohexyl-H-2a, 2e, 6a, 6e), 1.57 (s, 3H, -CO-CH3), 1.37-1.42 (m, 1H, Cyclohexyl-H-
3e),1.27-1.31 (m, 1H, Cyclohexyl-H-5e) 1.25 (s, 3H, CH3), 0.86-0.92 (m, 1H, Cyclohexyl-H-3
a); 
13C NMR (125 MHz, CDCl3) δ 170.70, 170.20 (-CO-CH3), 169.49 (-CO-OCH3), 165.89 (-CO-
N-), 134.37, 133.16, 131.31, 129.88, 129.77, 129.67, 128.42, 128.36, 127.47, 123.61 (Ar), 
100.36 (pyr), 98.69 (Cgal-1), 96.65 (Cglu-1), 96.12 (Cyclohexyl-C-1), 95.91 (Cyclohexyl-C-4), 
72.04 (Cgal-4), 71.93 (Cgal-5), 71.79 (Cglu-5), 70.82 (Cgal-3), 69.22 (Cglu-3), 69.13 (Cgal-4), 66.7 
(Cgal-2), 65.34 (Cgal-6), 64.01 (Cglu-6), 62.17 (Cglu-2), 54.8 (CO-OCH3), 31.93, 29.70, 29.36, 
28.98 (Cyclohexyl-C-2, 3, 5, 6), 25.72 (CH3), 20.78, 20.65, 20.47 (-CO-CH3); HRMS (ESI): 
Calcd C45H51NO20Na for (M+Na)
+: 948.2902. Found: 948.2899. 
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4.2.  6-O-p-toluenesulfonyl-D-arabino-hex-1-enitol (17). 
      To a solution of D-glucal (7.6 g, 52.5 mmol) in anhydrous pyridine was added dropwise a 
solution of p-toluenesulfonyl chloride (15.02 g, 78.8 mmol) in anhydrous CH2Cl2 at 0 
oC upon 
vigorous stirring. The reaction was terminated after 3 h by the addition of water, followed by 
washing with saturated CuSO4 (3 x 30 mL), water (5 x 30 mL) and brine (1 x 30 mL). The 
organic extracts were dried under anhydrous MgSO4 and concentrated in vacuo to yield crude 
17. Although the compound was synthesized earlier,13 no spectroscopic data was reported. The 
product was purified by flash chromatography using 3%, 4% and 5% CH3OH in CHCl3 mixtures 
to give 8.18 g (56% yield) of 17 as a colorless oily mass which crystallized upon freezing: Rf 
(1:20 CH3OH/CHCl3): 0.46; mp 50–51 oC; 1H NMR (500 MHz, CDCl3) δ 7.81 (d, 2H, J = 6.3 
Hz, Ar), 7.35 (d, 2H, J = 7.9 Hz, Ar), 6.24 (d, 1H, J1,2 = 6.1, J1,3 = 1.8 Hz, H-1), 4.74 (dd, 1H, J2,1 
= 6.3, J2,3 = 2.2 Hz, H-2), 4.47 (dd, 1H, J6,6’ = 11.25, J6,5 = 4Hz, H-6), 4.28 (dd, 1H, J6,6’ = 11.45, 
J6’,5 = 2.5 Hz, H-6’), 4.26 (d, 1H, J3,4 = 6.8 Hz, H-3), 3.91 (ddd, 1H, J5,4 = 9.75, J5,6 = 3.9, J5,6’ = 2 
Hz, H-5), 3.76 (dd, 1H, J4,3 = 8.3, J4,5 =8.3 Hz, H-4), 3.09 (s, 1H, 4-OH), 2.45 (s, 3H, PhCH3), 
2.23 (s, 1H, 3-OH); 13C NMR (125 MHz, CDCl3) δ 145.19 (CH, Ar), 143.99 (C-1), 132.61, 
129.93 , 128.02 (CH, Ar), 103.04 (C-2), 75.7 (C-5), 69.57 (C-3), 69.35 (C-4), 67.92 (C-6), 21.66 
(PhCH3). 
4.3. 3,6-Anhydro-2-deoxy-D-arabino-hex-1-enitol (18).                                                                  
     To a solution of 17 (200 mg, 0.33 mmol) in 20 mL of tetrahydrofuran (THF) was added 
dropwise 0.83 mL of 2.4 M LiAlH4 in THF (2 mmol) at 0 
oC. The mixture was refluxed at 73 oC 
for two days. It was then cooled to 0 oC and neutralized with 15% w/v NaOH and water, and 
filtered through a Celite@ bed upon dilution with ethyl acetate (EtOAc). The mixture was 
concentrated in vacuo and the product was purified by flash chromatography using 1:1 mixture 
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of EtOAc/Hexanes to give 73 mg (84%) of 18 as a white solid: Rf (1:20 CH3OH/CHCl3): 0.42; 
D]
22 -24.17 (c 0.58, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 6.54 (d, 1H, J1,2 = 5.0 Hz, H-1), 
5.02 (ddd, 1H, J2,1 = 5.25, J2,3 = 5.5,  J2,4 = 1.5 Hz, H-2), 4.36 (br dd, 1H, J5,6 =3.65, J5,6’ =3.65 
Hz, H-5), 4.27 (d, 1H, J6’,6 =11.2 Hz, H-6’), 4.23-4.2 (m, 1H, H-4), 4.18 (dd, 1H, J6,6’ = 11.3, J5,6 
= 4.5 Hz, H-6), 4.03 (br dd, 1H, J3,4 =4.5, J3,2= 5.5 Hz, H-3), 2.09 (d, 1H, J4,-OH = 10.7 Hz, 4-OH); 
13C NMR (125 MHz, CDCl3) δ 146.53 (C-1), 100.41 (C-2), 76.56 (C-5), 74.71 (C-6), 68.76 (C-
3), 66.26 (C-4); Anal. Calcd. for C6H8O3: C, 56.24; H, 6.29. Found: C, 56.15; H, 6.42.       
4.4 . General procedure for the synthesis of 3,6-anhydro-O-glycosides. 
    To a solution of 50 mg (0.39 mmol) of 18 in 5 mL of anhydrous CH3CN at 0 
oC was added 
105.5 mg (0.47mmol) of N-iodosuccinimide. To the solution was then added 1.2 equivalents of 
the desired nucleophile and the reaction mixture was stirred at r. t. overnight. The solvent was 
evaporated in vacuo and the crude product was purified by preparatory thin-layer 
chromatography (TLC) using 1:50 CH3OH/CHCl3 as the solvent.  
4.4.1. Methyl-3,6-anhydro-2-deoxy-2-iodo-gluco- and manno-pyranosides (19a, 19b, 19c). 
     Data for the mixture of diastereomers: 1H NMR (500 MHz, CDCl3) δ 5.31 (s, 1H), 5.03 (d, 
1H, J = 7.8 Hz), 4.72 (s, 1H), 4.47 (dd, 1H, J = 4.4 Hz, J = 3.4 Hz), 4.42-4.44 (m, 1H), 4.39-4.36 
(m, 2H), 4.28-4.32 (m, 2H), 4.24 (d, 2H, J = 10.7 Hz), 4.15-4.12 (m, 1H), 4.09-4.06 (m, 3H), 
3.96 (dd, 1H, J = 10 Hz, J = 5 Hz), 3.91 (dd, 1H, J = 5 Hz, J = 10 Hz), 3.54 (s, 1H), 3.48 (s, 1H), 
3.46 (s, 1H), 2.64 (d, 1H, J = 8.8 Hz), 2.44 (d, 1H, J = 5 Hz), 2.41 (d, 1H, J = 8.8 Hz), 2.04 (d, 
1H, J = 5.3 Hz); 13C NMR (125 MHz, CDCl3) δ 80.43, 72.81, 69.06, 29.57, 26.60, 20.28; HRMS 
(ESI): Calcd C7H11O4NaI for (M+Na)
+: 308.9611. Found: 308.9600. 
 
4.5. General procedure for the synthesis of 2-deoxythioglycosides. 
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     To a stirred solution of 50 mg (0.39 mmol) of 18 and 21 mg (0.039 mmol) of Ce(NH4)2(NO3)6 
in anhydrous CH3CN (5 mL) was added a solution of 0.2 mL (1.95 mmol) of PhSH in anhydrous 
CH3CN (5 mL) at 0 
oC and allowed to stir overnight at r.t.. The solvent was evaporated in vacuo 
and the residue was diluted with excess CH2Cl2, washed with 10% NaOH, saturated NaHCO3 
and saturated NaCl and, dried over anhydrous Na2SO4. The organic solvent was evaporated in 
vacuo and the crude (150 mg) obtained was purified by preparatory TLC using 1:50 
CH3OH/CHCl3 as the solvent to give mixtures of compounds 20a, 20b (60 mg) and 21a, 21b (33 
mg). 
4.5.1. Thiophenyl-3,6-anhydro-2-deoxy-D-glucopyranoside (20a, 20b).                                        
    Data for α-anomer (20b): Rf (1:50 CH3OH/CHCl3): 0.84; 1H NMR (500 MHz, CDCl3) δ 7.54-
7.50 (m, 2H, Ar), 7.33-7.24 (m, 3H, Ar), 5.73 (dd, 1H, J1,2 = 8.0, J1,2’ = 3.2 Hz, H-1), 4.69-4.67 
(m, 1H, H-5), 4.59 (dd, 1H, J2,3 = 5.4, J3,4 = 1.2 Hz, H-3), 4.29-4.26 (m, 1H, H-4), 3.99 (dd, 1H, 
J6,6’ = 9.7, J5,6 = 4.4 Hz, H-6), 3.84 (dd, 1H, J6,6’ = 9, J5,6’ = 5.5 Hz, H-6’), 3.06 (d, 1H, J4,-OH = 
10.7 Hz, 4-OH), 2.63 (ddd, 1H, J2,2’ = 14.15, J1,2 = 8.55, J2,3 = 6.3 Hz, H-2), 2.35 (ddd, 1H, J2,2’ = 
14.1, J1,2’ = 3.15, J2’,3 = 1.3 Hz, H-2’); 13C NMR (125 MHz, CDCl3) δ 132.3, 130.8, 129.1 (CH, 
Ar), 89.8 (C-1), 85.17 (C-5), 82.9 (C-3), 74.86 (C-6), 71.83 (C-4), 40.6 (C-2); HRMS (ESI): 
Calcd C12H14O3NaS for (M+Na)
+: 261.0570. Found: 261.0561. Data for β-anomer (20a): Rf 
(1:50 CH3OH/CHCl3): 0.76; 
1H NMR (500 MHz, CDCl3) δ 7.54-7.50 (m, 2H, Ar), 7.33-7.24 (m, 
3H, Ar), 5.66 (dd, 1H, J1,2 = 6.8, J1,2’ = 1.3 Hz, H-1), 4.69-4.67 (m, 1H, H-5), 4.64 (dd, 1H, J3,4 = 
5.4, J2,3 = 1.2 Hz, H-3), 4.26-4.25 (m, 1H, H-4), 3.82 (dd, 1H, J6,6’ = 9.55, J5,6’ = 5.7 Hz, H-6’), 
3.63 (dd, 1H, J6,6’ = 9.5, J5,6 = 6.2 Hz, H-6), 2.58 (d, 1H, J4,-OH = 7.4 Hz, 4-OH), 2.5 (ddd, 1H, 
J2,2’ = 14.1, J1,2 = 6.35, J2,3 = 2 Hz, H-2), 2.17-2.22 (m, 1H, H-2’); 13C NMR (125 MHz, CDCl3) δ 
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129, 127.78, 127.35 (CH, Ar), 88.41 (C-1), 82.52 (C-5), 82.39 (C-3), 73.16 (C-6), 72.12 (C-4), 
40.77 (C-2); HRMS (ESI): Calcd C12H14O3NaS for (M+Na)
+: 261.0570. Found: 261.0561. 
4.5.2. Thiophenyl-2,3-dideoxy-D-glucopyranoside (21a, 21b).                                                                  
     Data for α-anomer (21a): Rf (1:50 CH3OH/CHCl3): 0.19; 1H NMR (500 MHz, CDCl3) δ 
7.51-7.53 (m, 2H, Ar), 7.26-7.33 (m, 3H, Ar), 6.0 (dd, 1H, J1,2 = 10.2 Hz, J2,3 = 2 Hz, H-2), 5.98 
(d, 1H, J1,2 = 10.2 Hz, H-1), 5.74 (dd, 1H, J3,4 = 1.2 Hz, J2,3 = 2.7 Hz, H-3), 4.32 (dd, 1H, J3,4 = 2 
Hz, J4,5 = 8.75 Hz, H-4), 4.03-4.07 (m, 1H, H-5), 3.86-3.92 (m, 2H, H-6, 6’), 1.85 (d, 1H, J4,-OH = 
7.3 Hz, 4-OH), 1.82 (dd, 1H, J6,-OH = 6.35 Hz, J6’,-OH = 6.4 Hz, 6-OH); 
13C NMR (125 MHz, 
CDCl3) δ 131.77, 129.03, 127.32 (CH, Ar), 131.72 (C-1), 127.12 (C-2), 83.61 (C-3), 71.88 (C-5), 
64.29 (C-4), 62.91 (C-6); HRMS (ESI): Calcd C12H14O3NaS for (M+Na)
+: 261.0561. Found: 
261.0561. Data for β-anomer (21b): Rf (1:50 CH3OH/CHCl3): 0.19; 1H NMR (500 MHz, 
CDCl3) δ 7.51-7.53 (m, 2H, Ar), 7.26-7.33 (m, 3H, Ar), 5.88 (dd, 1H, J1,2 = 2 Hz, J2,3 = 1.9 Hz, 
H-2), 5.86 (dd, 1H, J1,2 = 1.5 Hz, J2,3 = 1.4 Hz, H-1), 4.72-4.78 (m, 1H, H-4), 4.54-4.60 (m, 1H, 
H-5), 4.11-4.16 (m, 2H, H-6, 6’), 2.18-2.24 (m, 4-OH, 6-OH); 13C NMR (125 MHz, CDCl3) δ 
135.10, 132.5, 131.69 (CH, Ar), 131.62 (C-1), 128.84 (C-2), 81.74 (C-3), 79.74 (C-5), 63.40 (C-
4), 62.75 (C-6); HRMS (ESI): Calcd C12H14O3NaS for (M+Na)
+: 261.0561. Found: 261.0561. 
4.6. General procedure for the preparation of the dianhydrosugar. 
     To 100 mg (0.78 mmol) of 18 in 10 mL of CH3CN was added 210 mg (0.94 mmol) of N-
iodosuccinimide in the presence of 4 Ǻ molecular sieves, and allowed to stir overnight at r.t. The 
solvent was removed in vacuo and the residue was diluted with excess CH2Cl2, washed with 10% 
Na2S2O3, saturated NaCl and dried over anhydrous Na2SO4. The organic filtrate was evaporated 
in vacuo and the crude product (170 mg) was purified by flash chromatography using 2:3 
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EtOAc/Hexanes to give 150 mg (0.61 mmol, 76 %) of 22. In the absence of activated sieves, a 
mixture of 2-deoxy-2-iodo-hexopyranoses (23a-c), were also obtained (30%). 
4.6.1. 1,4:3,6-Dianhydro-2-deoxy-2-iodo-D-glucopyranose (22). 
     Data for the dianhydrosugar: Rf (1:50 CH3OH/CHCl3): 0.9; 
1H NMR (500 MHz, CDCl3) δ 
5.51 (br s, 1H, H-1), 5.09 (dd, 1H, J4,3= 4.25, J4,5 = 4.5 Hz, H-4), 4.27 (dd, 1H, J5,4 = 3.5, J5,6 = 
3.25 Hz, H-5), 4.18 (dd, 1H, J3,2 = 7.0, J3,4 = 5.0 Hz, H-3), 4.15 (d, 1H, J6,6’ = 10.8 Hz, H-6’), 4.0 
(dd, 1H, J2,3 = 7.0, J2,1 = 2.0 Hz, H-2), 3.94 (dd, 1H, J6,6’ =10.7, J5,6 = 3.0 Hz, H-6); 
13C NMR 
(125 MHz, CDCl3) δ 100.20 (C-1), 79.87 (C-4), 77.02 (C-5), 73.28 (C-3), 71.30 (C-6), 32.85 (C-
2); LRMS (ESI) m/Z (rel. intensity) 254.9 (M+H)+ (79). 
4.6.2. 3,6-anhydro-2-deoxy-2-iodo-D-hexopyranose (23a, 23b, 23c). 
      Data for mixture of diastereomers: Rf 1:50 CH3OH/CHCl3): 0.12; 
1H NMR (500 MHz, 
CDCl3) δ 5.76 (s, 1H), 5.68 (d, 1H, J = 5 Hz), 5.38 (s, 1H), 5.02 (dd, 1H, J = 5.4 Hz, J = 4.9 Hz), 
4.89 (d, 1H, J =), 4.83 (ddd, 1H, J = 15 Hz, J = 5 Hz, J = 5 Hz), 4.73-4.70 (m, 2H), 4.48 (d, 1H, J 
= 1.4 Hz), 4.44 (d, 1H, J = 4.9 Hz), 4.40-4.37 (m, 2H), 4.19 (dd, 1H, J = 4.9 Hz, J = 4.4 Hz), 4.14 
(dd, 1H, J =), 4.09-4.06 (m, 2H), 4.04-3.98 (m, 2H), 3.79-3.76 (m, 2H), 3.62 (dd, 1H, J = 9.5 Hz, 
J = 6.6 Hz); 13C NMR (125 MHz, CDCl3) δ 107.69, 99.48, 96.06, 90.68, 84.04, 83.32, 82.26, 
76.37, 75.55, 71.75, 70.55, 46.57, 46.56, 26.66, 25.12, 23.61, 8.72, 8.71; LRMS (ESI): Calcd 
C6H9IO4: 271.9. Found for (M+Na)
+: 294.8.  
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                                                          4.2  NMR Spectra 
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